var title_f15_2_15392="Corneal clouding";
var content_f15_2_15392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal clouding in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The eye in a 17-year-old male with Hurler-Scheie syndrome. Severe grainy corneal clouding is apparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15392=[""].join("\n");
var outline_f15_2_15392=null;
var title_f15_2_15393="Patient information: Rectovaginal fistula (The Basics)";
var content_f15_2_15393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83449\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/45/32465\">",
"         Rectovaginal fistula",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rectovaginal fistula (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rectovaginal-fistula-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H114039403\">",
"      <span class=\"h1\">",
"       What is a rectovaginal fistula?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A rectovaginal fistula is an abnormal connection between the lower part of the large intestine (rectum) and the vagina (",
"      <a class=\"graphic graphic_figure graphicRef83275 \" href=\"UTD.htm?31/45/32465\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114039418\">",
"      <span class=\"h1\">",
"       What are the symptoms of a rectovaginal fistula?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Small rectovaginal fistulas might not have symptoms. But the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Gas or bowel movements passing out of the vagina",
"       </li>",
"       <li>",
"        A bad smell coming from the vagina",
"       </li>",
"       <li>",
"        Pain or irritation in or near the vagina",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114039433\">",
"      <span class=\"h1\">",
"       Are there tests for a rectovaginal fistula?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse might be able to tell if you have it by learning about your symptoms and doing an exam. For the exam, the doctor will put gloved fingers inside your vagina and your anus at the same time.",
"     </p>",
"     <p>",
"      But you might need tests that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A dye test - For this test, the doctor or nurse uses a blunt needle to put a blue dye into your rectum. He or she then checks for blue dye in your vagina.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Proctoscopy &ndash;For this test, the doctor puts a narrow tube with a light at the end into the rectum to check the area.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Imaging tests, such as an MRI or a CT scan - These tests create pictures of the inside of the body. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114039448\">",
"      <span class=\"h1\">",
"       How is a rectovaginal fistula treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rectovaginal fistulas are treated with surgery to close and repair the fistula. After surgery, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Drink only fluids for several days",
"       </li>",
"       <li>",
"        Eat foods that will help you have fewer and smaller bowel movements. Your doctor or nurse will tell you more about this diet and how long you need to stay on it.",
"       </li>",
"       <li>",
"        Take &ldquo;sitz&rdquo; baths - This is a shallow, warm bath that helps clean and heal the vaginal area. Take them twice a day for 30 minutes each for 2 to 3 days.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114039463\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Talk to your doctor or midwife. If you get pregnant, he or she might recommend that you have a c-section (surgery to get the baby out) instead of giving birth to the baby through your vagina.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/2/15393?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83449 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15393=[""].join("\n");
var outline_f15_2_15393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114039403\">",
"      What is a rectovaginal fistula?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114039418\">",
"      What are the symptoms of a rectovaginal fistula?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114039433\">",
"      Are there tests for a rectovaginal fistula?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114039448\">",
"      How is a rectovaginal fistula treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114039463\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/45/32465\">",
"      Rectovaginal fistula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15394="Patient information: Outer ear infection (The Basics)";
var content_f15_2_15394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15736\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\">",
"         Normal ear",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/38/44642\">",
"         Patient information: Ear infections (otitis media) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/57/10130\">",
"         Patient information: Removing objects stuck in the ear (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/16/15619\">",
"         Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/12/26816\">",
"         Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Outer ear infection (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/outer-ear-infection-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1481201290\">",
"      <span class=\"h1\">",
"       What is an outer ear infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An outer ear infection is a condition that can cause pain in the ear canal. The ear canal is the part of the ear that goes from the side of the head to the eardrum (",
"      <a class=\"graphic graphic_figure graphicRef55121 \" href=\"UTD.htm?29/61/30677\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      An outer ear infection is sometimes called &ldquo;swimmer&rsquo;s ear.&rdquo; But an outer ear infection does not happen only in people who swim. People who do not swim can also get it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201297\">",
"      <span class=\"h1\">",
"       What causes an outer ear infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An outer ear infection happens when the skin in the ear canal gets irritated or scratched, and then gets infected. This can happen when a person:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Puts cotton swabs, fingers, or other things inside the ear",
"       </li>",
"       <li>",
"        Cleans the ear canal to remove ear wax",
"       </li>",
"       <li>",
"        Swims on a regular basis &ndash; Water can soften the ear canal, which allows germs to infect the skin more easily.",
"       </li>",
"       <li>",
"        Wears hearing aids, headphones, or ear plugs that can hurt the skin inside the ear",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201304\">",
"      <span class=\"h1\">",
"       What are the symptoms of an outer ear infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain inside the ear, especially when the ear is pulled or moved",
"       </li>",
"       <li>",
"        Itching inside the ear",
"       </li>",
"       <li>",
"        Fluid or pus leaking from the ear",
"       </li>",
"       <li>",
"        Trouble hearing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201311\">",
"      <span class=\"h1\">",
"       Is there a test for an outer ear infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and looking in your ear. During the visit, your doctor might clean out your ear so that it can heal more quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201318\">",
"      <span class=\"h1\">",
"       How is an outer ear infection treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Ear drops &ndash; Be sure to finish all the medicine, even if you feel better after a few days. When you use ear drops, you should:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Lie on your side or tilt your head",
"       </li>",
"       <li>",
"        Make sure the ear drops go into the ear canal",
"       </li>",
"       <li>",
"        Stay in the same position or put a cotton ball in the ear for 20 minutes (after the ear drops are in)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to relieve pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201325\">",
"      <span class=\"h1\">",
"       What else should I do during treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to keep the inside of your ear dry while the infection heals. You should not swim for 7 to 10 days after starting treatment. But you can take a shower. To keep the ear dry during a shower, put some petroleum jelly (Vaseline) on a cotton ball, and then put the cotton ball in your ear.",
"     </p>",
"     <p>",
"      You should also avoid wearing hearing aids or headphones in the infected ear until your symptoms improve.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201332\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your symptoms get worse",
"       </li>",
"       <li>",
"        Your symptoms are not better 2 days after starting treatment",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201339\">",
"      <span class=\"h1\">",
"       Can an outer ear infection be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting an outer ear infection by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not sticking things in your ears or cleaning inside your ears &ndash; The inside of the ears do not usually need to be cleaned. It is normal to have some ear wax in your ears. Ear wax protects the ear canal. But if you are worried that you have too much ear wax, talk to your doctor or nurse. He or she can look in your ears and tell you how to clean them safely.",
"       </li>",
"       <li>",
"        Following these tips if you swim a lot:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Blow dry or shake your ears dry after you swim",
"       </li>",
"       <li>",
"        Use ear drops that can prevent infections after you swim",
"       </li>",
"       <li>",
"        Wear ear plugs to prevent water from getting in your ears",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481201346\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       Patient information: Ear infections (otitis media) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=see_link\">",
"       Patient information: Removing objects stuck in the ear (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=see_link\">",
"       Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/2/15394?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15736 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-72FD83CAD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15394=[""].join("\n");
var outline_f15_2_15394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201290\">",
"      What is an outer ear infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201297\">",
"      What causes an outer ear infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201304\">",
"      What are the symptoms of an outer ear infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201311\">",
"      Is there a test for an outer ear infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201318\">",
"      How is an outer ear infection treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201325\">",
"      What else should I do during treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201332\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201339\">",
"      Can an outer ear infection be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481201346\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15736\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\">",
"      Normal ear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=related_link\">",
"      Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=related_link\">",
"      Patient information: Removing objects stuck in the ear (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15395="Tuberculin skin test: Patient drug information";
var content_f15_2_15395=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tuberculin skin test: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     see \"Tuberculin skin test: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aplisol&reg;;",
"     </li>",
"     <li>",
"      Tubersol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691295",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during a TB (tuberculosis) test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tuberculin purified protein derivative (PPD) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a very bad reaction to a tuberculin test in the past.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot under the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696332",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You must see your doctor 2 to 3 days after the test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10971 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15395=[""].join("\n");
var outline_f15_2_15395=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232324\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012507\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012506\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012510\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012511\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012513\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012509\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012515\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=related_link\">",
"      Tuberculin skin test: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15396="Photokeratitis";
var content_f15_2_15396=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Photokeratitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15396/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15396/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15396/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15396/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15396/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15396/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/2/15396/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photokeratitis, also known as ultraviolet keratitis or UV keratitis, is an acute syndrome that occurs after ultraviolet irradiation of the eyes. The exposure may not be initially apparent to the patient, as there is a latent period (6 to 12 hours) between exposure and onset of symptoms. Although intensely painful, photokeratitis is generally a self-limited condition with complete resolution.",
"   </p>",
"   <p>",
"    The presentation, diagnosis, treatment, and prevention of photokeratitis will be reviewed here. The general evaluation of patients with a red eye is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF ULTRAVIOLET EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many recreational and occupational activities are associated with ultraviolet exposure and the potential for photokeratitis in unprotected eyes. Welder's arc burns and snowblindness are the best known examples of photokeratitis, but other exposures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other recreational solar exposure",
"     </li>",
"     <li>",
"      Sunlamps",
"     </li>",
"     <li>",
"      Short circuit in a high voltage line",
"     </li>",
"     <li>",
"      Laboratory or germicidal ultraviolet lamps",
"     </li>",
"     <li>",
"      Damaged metal halide lamps, typically used in gymnasia and assembly halls [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aquaria disinfection lamps [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The affected patient is not aware of the radiation insult until 6 to 12 hours after the exposure, when the patient develops bilateral eye pain, injection, photophobia, and inability to open the eyes. The latency is absolutely characteristic. Associated facial erythema and edema are often present and suggest radiation exposure as the source of the injury. The patient is typically distraught and pacing or rocking, due to severe pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornea transmits most light in the visible spectrum, but absorbs light in the ultraviolet spectrum. This absorption occurs primarily in the multilayered corneal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/4\">",
"     4",
"    </a>",
"    ] and results in surface epithelial cell death and desquamation within hours.",
"   </p>",
"   <p>",
"    UV-A (320 to 400 nm) falls into the part of the spectrum that is only 10 to 20 percent absorbed by the cornea, whereas the cornea absorbs nearly 100 percent of UV-C (&lt;290 nm). The clinical findings associated with solar UV photokeratitis are related to exposures at approximately 290 nm (the cut-off between UV-B and UV-C), energy that is mostly absorbed by the corneal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epithelial nociceptor terminal axons are destroyed by the exposure. Corneal pain results from stimulation, in the absence of epithelium, of the sub-epithelial nerve plexus by a variety of environmental insults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regeneration of the epithelial surface and resolution of signs and symptoms occurs within 24 to 72 hours. Studies in animal models reveal that this rapid response is due to macrophage migration inhibitory factor (MIF), an integral component of the host alarm system and stress response, and a contributor to wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history will typically yield the antecedent exposure along with failure to use protective eyewear. The eye pain is associated with photophobia and foreign body sensation, symptoms that are characteristic of a keratitis. Photokeratitis is typically bilateral and involves most of the corneal surface, which accounts for the incapacitating nature of this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be erythema of the face and lids. Visual acuity is typically mildly to moderately reduced, but may be difficult to obtain without administration of topical anesthetic.",
"   </p>",
"   <p>",
"    Penlight examination reveals tearing, and generalized injection and edema (chemosis) of the bulbar conjunctiva. There is no discharge or involvement of the tarsal conjunctiva, which distinguishes photokeratitis from conjunctivitis.",
"   </p>",
"   <p>",
"    The cornea may appear mildly hazy. Instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    reveals superficial punctuate staining of the cornea in the interpalpebral fissure. The pupils may be miotic. The remainder of the eye examination is unremarkable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of photokeratitis is supportive, with acknowledgment that the pain related to this syndrome is severe (anecdotally reported as comparable to childbirth or a kidney stone). There is no evidence from clinical trials on the efficacy of various treatment options. Initial treatment with oral analgesics and lubricant antibiotic ointments can be undertaken by the primary care or emergency clinician. &nbsp;",
"   </p>",
"   <p>",
"    Supportive care includes: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral analgesics &mdash; The pain from photokeratitis is typically severe, especially at the onset. Mild oral opioids are usually necessary for adequate pain relief. We suggest that patients are given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      5 to 10 mg every 4 to 6 hours as needed for the first 24 to 48 hours. Pain control permits sleep and helps recovery.",
"     </li>",
"     <li>",
"      Lubricant antibiotic ointments &mdash; Topical antibiotic ointments can improve comfort and may provide prophylaxis against superinfection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/8\">",
"       8",
"      </a>",
"      ]. We suggest treating patients with an antibiotic ointment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      , or polymyxin-bacitracin), prescribed three to four times daily for two to three days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be re-examined in one to two days for resolution of signs and symptoms. They should be referred to an ophthalmologist for any new or persistent signs or symptoms.",
"   </p>",
"   <p>",
"    Photophobia can be relieved with cycloplegic drops (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=see_link\">",
"     cyclopentolate",
"    </a>",
"    1 percent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/43/35508?source=see_link\">",
"     homatropine",
"    </a>",
"    2 to 5 percent, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    0.25 percent). However, these agents can result in pupil dilation lasting days, which may be distressing to the patient. We suggest that patients NOT be treated with cycloplegics. &nbsp;Pressure patching of the worse eye may offer some relief. However, it has not been proven to speed healing after corneal abrasion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/9\">",
"     9",
"    </a>",
"    ], and is unlikely to improve healing after UV irradiation. We suggest that patients NOT be treated with eye patching.",
"   </p>",
"   <p>",
"    We recommend that topical anesthetics NOT be dispensed or prescribed, although they may be used during the initial examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/10\">",
"     10",
"    </a>",
"    ]. Continued use can lead to dependency, corneal toxicity, persistent corneal epithelial defects, corneal ulceration, and loss of the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/10\">",
"     10",
"    </a>",
"    ]. Corneal anesthesia, whether pathologic or pharmacologic, can lead to neurotrophic ulceration related to the absence of neural input that generates protective reflexes, including tearing and blinking. Neurotrophic keratitis is analogous to foot ulcers seen in diabetic neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional teaching is that the cornea heals without sequelae after an episode of photokeratitis. However, this has never been studied systematically or with regard to the particular spectra of differing ultraviolet sources.",
"   </p>",
"   <p>",
"    Long-term effects of chronic solar ultraviolet exposure to the cornea include pterygium and a rare corneal degeneration (climatic droplet keratopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/11\">",
"     11",
"    </a>",
"    ]. However, an association of these syndromes with prior acute episodes of photokeratitis has never been shown.",
"   </p>",
"   <p>",
"    A disproportionate number of radiation-associated eye conditions occur in welders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/12\">",
"     12",
"    </a>",
"    ], but again, association with prior acute episodes has not been shown. UV radiation can cause damage to the corneal endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/13\">",
"     13",
"    </a>",
"    ]. However, one study that compared welders with office workers found no evidence of increased endothelial damage among the welders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse health effects of UV radiation, other than photokeratitis, include erythema, pterygium, some types of cataract, non-melanocytic skin cancer, and cutaneous malignant melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photokeratitis is preventable. Those with recreational exposure should use well-fitting sunglasses that block most UV-A and UV-B radiation and meet the American National Standards Institute (ANSI) standards for non-prescription and prescription sunglasses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/16\">",
"     16",
"    </a>",
"    ] or equivalent standards outside the United States.",
"   </p>",
"   <p>",
"    UV-blocking glasses or contact lenses should NOT be used when occupational exposures require UV-blocking safety goggles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/15\">",
"     15",
"    </a>",
"    ]. Those with potential face and occupational exposures should use protectors meeting ANSI standards for Eye and Face Protectors and for Occupations and Educational Personal Eye and Face Protection Devices. These measures are considered to provide adequate protection for most workers exposed to solar and artificial solar UV sources [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/15\">",
"     15",
"    </a>",
"    ]. Facilities using metal halide and mercury vapor lamps should adhere to FDA radiological health program recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15396/abstract/17\">",
"     17",
"    </a>",
"    ] or equivalent international standards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/61/29649?source=see_link\">",
"       \"Patient information: Photokeratitis (Arc eye) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Photokeratitis (ultraviolet keratitis) is an acute syndrome causing severe eye pain that begins 6 to 12 hours after exposure to ultraviolet light. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surface layer of the corneal epithelium is desquamated, exposing subepithelial nerve endings; the surface regenerates with resolution of symptoms in 24 to 72 hours. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients often have a foreign body sensation;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      staining may show punctate corneal staining. There is generalized eye injection and edema, and some patients have facial and lid erythema. Eye discharge should not be present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest patients with photokeratitis be treated supportively with antibiotic ointment and oral analgesics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend that topical anesthetics should NOT be dispensed or prescribed, although they may be used during the initial examination (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest patients NOT be treated with cycloplegics or eye patching (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photokeratitis is preventable. Protective eyewear should be worn for occupational or recreational exposure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/1\">",
"      Kirschke DL, Jones TF, Smith NM, Schaffner W. Photokeratitis and UV-radiation burns associated with damaged metal halide lamps. Arch Pediatr Adolesc Med 2004; 158:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/2\">",
"      Banerjee S, Patwardhan A, Savant VV. Mass photokeratitis following exposure to unprotected ultraviolet light. J Public Health Med 2003; 25:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/3\">",
"      Verma AS, Dwarika D, Bhola RM, Emamali S. Photokeratitis following the manipulation of aquaria disinfection lamps. Emerg Med J 2007; 24:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/4\">",
"      Podskochy A. Protective role of corneal epithelium against ultraviolet radiation damage. Acta Ophthalmol Scand 2004; 82:714.",
"     </a>",
"    </li>",
"    <li>",
"     Parrish CM, Chandler JW. Corneal trauma. In: The Cornea, Kaufman HE, et al (Eds), Churchill Livingstone, New York 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/6\">",
"      Bergmanson JP. Corneal damage in photokeratitis--why is it so painful? Optom Vis Sci 1990; 67:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/7\">",
"      Kitaichi N, Shimizu T, Yoshida K, et al. Macrophage migration inhibitory factor ameliorates UV-induced photokeratitis in mice. Exp Eye Res 2008; 86:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/8\">",
"      Upadhyay MP, Karmacharya PC, Koirala S, et al. The Bhaktapur eye study: ocular trauma and antibiotic prophylaxis for the prevention of corneal ulceration in Nepal. Br J Ophthalmol 2001; 85:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/9\">",
"      Turner A, Rabiu M. Patching for corneal abrasion. Cochrane Database Syst Rev 2006; :CD004764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/10\">",
"      McGee HT, Fraunfelder FW. Toxicities of topical ophthalmic anesthetics. Expert Opin Drug Saf 2007; 6:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/11\">",
"      Cullen AP. Photokeratitis and other phototoxic effects on the cornea and conjunctiva. Int J Toxicol 2002; 21:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/12\">",
"      Tenkate TD. Optical radiation hazards of welding arcs. Rev Environ Health 1998; 13:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/13\">",
"      Karai I, Matsumura S, Takise S, et al. Morphological change in the corneal endothelium due to ultraviolet radiation in welders. Br J Ophthalmol 1984; 68:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/14\">",
"      Oblak E, Doughty MJ. Chronic exposure to the ultraviolet radiation levels from arc welding does not result in obvious damage to the human corneal endothelium. Photochem Photobiol Sci 2002; 1:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15396/abstract/15\">",
"      Tenkate TD. Occupational exposure to ultraviolet radiation: a health risk assessment. Rev Environ Health 1999; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     www.ansi.org (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     Center for Devices and Radiological Health. Ultraviolet Radiation Burns from High Intensity Metal Halide and Mercury Vapor Lighting Remain a Public Health Concern. US Food and Drug Administration. Available at: www.fda.gov/cdrh/radhealth/products/urburns.html (Accessed on October 10, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6914 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15396=[""].join("\n");
var outline_f15_2_15396=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF ULTRAVIOLET EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/61/29649?source=related_link\">",
"      Patient information: Photokeratitis (Arc eye) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15397="Encopresis";
var content_f15_2_15397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Encopresis diagram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15397=[""].join("\n");
var outline_f15_2_15397=null;
var title_f15_2_15398="Varenicline: Drug information";
var content_f15_2_15398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Varenicline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/9/9365?source=see_link\">",
"    see \"Varenicline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15804398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Final Cardiovascular Safety Review",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is informing the public about the results of a large meta-analysis of clinical trials comparing patients who received Pfizer's smoking cessation drug, varenicline, to patients who received a placebo. The FDA had required Pfizer to conduct the meta-analysis to further evaluate the cardiovascular safety of the drug after first notifying the public about a possible increased risk of cardiovascular adverse events with varenicline in June 2011.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Cardiovascular events (a combined outcome of cardiovascular-related death, nonfatal myocardial infarction, and nonfatal stroke) in this meta-analysis were adjudicated by a blinded, independent committee. The analysis included just over 7000 patients (varenicline: 4190; placebo: 2812) across 15 randomized, double-blind, placebo-controlled studies and showed an increased incidence of 13 cases (0.31%) of major adverse cardiovascular events in patients using varenicline compared with placebo (6 cases; 0.21%), which did not reach clinical significance. These events were uncommon in both the varenicline and placebo groups. However, the data were analyzed many different ways and consistently showed a higher occurrence of events in patients using varenicline, which makes it seem more likely that it is related to the drug and not a chance finding.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare providers should weigh the risks versus the benefits of treating patients with varenicline. Patients should be instructed to seek medical attention if new or worsening symptoms of cardiovascular disease occur while receiving varenicline.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm331626.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm331626.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7999984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2975238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chantix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4104776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Champix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2975262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Partial Nicotine Agonist;",
"     </li>",
"     <li>",
"      Smoking Cessation Aid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2975291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Smoking cessation:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Days 1-3: 0.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Days 4-7: 0.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance (&ge; Day 8):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling: 1 mg twice daily for 11 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: 0.5-1 mg twice daily for 11 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Start 1 week before target quit date. Alternatively, patients may consider setting a quit date up to 35 days after initiation of varenicline (some data suggest that an extended pretreatment regimen may result in higher abstinence rates [Hajek, 2011]). If patient successfully quits smoking at the end of the 12 weeks, may continue for another 12 weeks to help maintain success. If not successful in first 12 weeks, then stop medication and reassess factors contributing to failure.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2975292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2975293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initiate: 0.5 mg once daily; maximum dose: 0.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     End-stage renal disease (ESRD) (receiving hemodialysis): Maximum dose: 0.5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2975294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F2975295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients who cannot tolerate adverse events may require temporary (or permanent) reduction in dose. Lower dose for a period of time, then may increase dose again or remain on lower dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2975300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chantix&reg;: Tablet: 0.5 mg (11s) [white tablets] and Tablet: 1 mg (42s) [light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chantix&reg;: 0.5 mg, 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2975240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7875058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088569.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088569.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2975297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Administer after eating and with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2975263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Smoking cessation:",
"     </b>",
"     Aid to smoking cessation treatment",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2975272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15% to 19%), insomnia (10% to 19%), abnormal dreams (9% to 13%), suicidal ideation (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (16% to 40%), vomiting (&le;5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris (4%), peripheral edema (2%), myocardial infarction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise (&le;7%), sleep disorder (&le;5%), drowsiness (3%), lethargy (1% to 2%), nightmares (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (6% to 9%), constipation (5% to 8%), dysgeusia (5% to 8%), abdominal pain (&le;7%), xerostomia (&le;6%), dyspepsia (5%), increased appetite (3% to 4%), anorexia (&le;2%), gastroesophageal reflux disease (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (5% to 7%), dyspnea (&le;2%), rhinorrhea (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute coronary syndrome, acute renal failure, amnesia, anemia, angioedema, asthma, atrial fibrillation, Bell's palsy, bradycardia, cardiac arrhythmia, cardiac flutter, cataract, cerebrovascular accident, conjunctivitis, cor pulmonale, coronary artery disease, deafness, delusions, depression, diabetes mellitus, dissociative disorder, dysarthria, dysphagia, ECG abnormality, eczema, enterocolitis, equilibrium disturbance, erectile dysfunction, erythema multiforme, gallbladder disease, gastric ulcer, gastrointestinal hemorrhage, hallucination, homicidal ideation, hostility, hyperhidrosis, hyperlipidemia, hypersensitivity, hypoglycemia, hypokalemia, intestinal obstruction, leukocytosis, loss of consciousness, lymphadenopathy, mania, Meniere's disease, migraine, multiple sclerosis, myositis, nephrolithiasis, nocturia, nocturnal amblyopia, nystagmus, ophthalmic vascular disease, oral mucosa ulcer, osteoporosis, pancreatitis, panic, photophobia, pleurisy, polyuria, psoriasis, psychomotor retardation, psychosis, psychotic reaction, pulmonary embolism, restless leg syndrome, seizure, skin photosensitivity, splenomegaly, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, thrombosis, thyroid disease, transient blindness, transient ischemic attacks, urinary retention, ventricular premature contractions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2975267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Serious hypersensitivity or skin reactions to varenicline or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2975268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). There have been postmarketing reports of traffic accidents, near-miss incidents in traffic, or other accidental injuries in patients taking varenicline. The FAA has banned varenicline for pilots and air traffic controllers, and the FMCSA, which governs the commercial trucking/busing industry, is advising against issuance of commercial operator licenses for individuals taking the drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing reports of hypersensitivity reactions (including angioedema) and rare cases of serious skin reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported. Patients should be instructed to discontinue use and contact healthcare provider if signs/symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nausea: Dose-dependent nausea may occur; both transient and persistent nausea has been reported. Dosage reduction may be considered for intolerable nausea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric effects:",
"     <b>",
"      [U.S. Boxed Warning]: Serious neuropsychiatric events (including depression, suicidal thoughts, and suicide) have been reported with use;",
"     </b>",
"     some cases may have been complicated by symptoms of nicotine withdrawal following smoking cessation. Smoking cessation (with or without treatment) is associated with nicotine withdrawal symptoms and the exacerbation of underlying psychiatric illness; however, some of the behavioral disturbances were reported in treated patients who continued to smoke. Neuropsychiatric symptoms (eg, mood disturbances, psychosis, hostility) have occurred in patients with and without pre-existing psychiatric disease; many cases resolved following therapy discontinuation although in some cases, symptoms persisted. Monitor all patients for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation); inform patients to discontinue treatment and contact their healthcare provider immediately if they experience any behavioral and/or mood changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: Treatment may increase risk of cardiovascular events. A meta-analysis of 15 clinical trials, including a placebo-controlled trial in patients with stable cardiovascular disease, showed an increased incidence of major cardiovascular events (combined outcome of cardiovascular-related death, nonfatal MI, nonfatal stroke) in patients using varenicline compared with placebo. Cardiovascular events were uncommon in both the varenicline and placebo groups. These findings did not reach statistical significance, although data was consistent. Events occurred primarily in patients with known cardiovascular disease. The meta-analysis also showed a lower incidence of all-cause and cardiovascular mortality in varenicline-treated patients, although this was not statistically significant either.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric illness: Patients with pre-existing psychiatric illness (eg, bipolar disorder, major severe depression, schizophrenia) were not studied in clinical trials; safety and efficacy has not been established in these populations. Due to rare neuropsychiatric events, caution is warranted if treatment is initiated; worsening of psychiatric illness has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol: Ethanol consumption may increase the risk of psychiatric adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nicotine: Safety and efficacy of varenicline with other smoking cessation therapies have not been established; increased adverse events when used concurrently with nicotine replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risk vs benefit:",
"     <b>",
"      [U.S. Boxed Warning]: Before prescribing, the risks of serious neuropsychiatric events must be weighed against the immediate and long term benefits of smoking abstinence for each patient.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2975278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Varenicline. Specifically, the risk for neuropsychiatric adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13140429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase the risk of psychiatric adverse events. Caution patients about the potential effects of ethanol consumption during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5544204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2975264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, decreased fertility, decreased fetal weight, and increased auditory startle response were observed in the offspring. There are no adequate or well-controlled studies in pregnant women. Use only if benefit outweighs the potential risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2975266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16113432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if varenicline is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2975296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Should be given with food and a full glass of water to decrease gastric upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chantix Continuing Month Pak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (56): $226.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chantix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (56): $226.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (56): $226.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chantix Starting Month Pak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 MG X 11 &amp; 1 MG X 42 (53): $226.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5657064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4108824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Champix (AR, AT, BE, BG, BR, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, EC, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PT, RU, SE, SG, SV, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2975282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Partial neuronal &alpha;",
"     <sub>",
"      4",
"     </sub>",
"     &beta;",
"     <sub>",
"      2",
"     </sub>",
"     nicotinic receptor agonist; prevents nicotine stimulation of mesolimbic dopamine system associated with nicotine addiction. Also binds to 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor (significance not determined) with moderate affinity. Varenicline stimulates dopamine activity but to a much smaller degree than nicotine does, resulting in decreased craving and withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2975284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; unaffected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &le;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal (&lt;10% of clearance is through metabolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (92% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Fiore M, Jaen CR, Baker TB, et al, &ldquo;A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update. A U.S. Public Health Service Report,&rdquo;",
"      <i>",
"       Am J Prev Med",
"      </i>",
"      , 2008,  35(2):158-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/2/15398/abstract-text/18617085/pubmed\" id=\"18617085\" target=\"_blank\">",
"        18617085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gonzales D, Rennard SI, Nides M, et al, &ldquo;Varenicline, an Alpha4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 296(1):47-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/2/15398/abstract-text/16820546/pubmed\" id=\"16820546\" target=\"_blank\">",
"        16820546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hajek P, McRobbie HJ, Myers KE, et al, &ldquo;Use of Varenicline for 4 Weeks Before Quitting Smoking: Decrease in",
"      <i>",
"       ad lib",
"      </i>",
"      Smoking and Increase in Smoking Cessation Rates,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2011, 171(8):770-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/2/15398/abstract-text/21518946/pubmed\" id=\"21518946\" target=\"_blank\">",
"        21518946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henningfield JE, Fant RV, Buchhalter JR, et al, &ldquo;Pharmacotherapy for Nicotine Dependence,&rdquo;",
"      <i>",
"       CA Cancer J Clin",
"      </i>",
"      , 2005, 55(5):281-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/2/15398/abstract-text/16166074/pubmed\" id=\"16166074\" target=\"_blank\">",
"        16166074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jorenby DE, Hays JT, Rigotti NA, et al, &ldquo;Efficacy of Varenicline, an Alpha4beta2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 296(1):56-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/2/15398/abstract-text/16820547/pubmed\" id=\"16820547\" target=\"_blank\">",
"        16820547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tonstad S, Tonneson P, Hajek P, et al, &ldquo;Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 296(1):64-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/2/15398/abstract-text/16820548/pubmed\" id=\"16820548\" target=\"_blank\">",
"        16820548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10339 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-E0F60D9195-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15398=[""].join("\n");
var outline_f15_2_15398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804398\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999984\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975238\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104776\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975262\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975291\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975292\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975293\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975294\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975295\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975300\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975240\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7875058\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975297\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975263\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975272\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975267\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975268\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300207\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975278\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13140429\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5544204\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975264\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975266\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16113432\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975296\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422182\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4108824\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975282\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975284\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/9/9365?source=related_link\">",
"      Varenicline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15399="Assessment of nutritional status in end-stage renal disease";
var content_f15_2_15399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of nutritional status in end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15399/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15399/contributors\">",
"     Marsha Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15399/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15399/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15399/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15399/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/2/15399/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending in part upon the method used and the population studied, from 40 to 70 percent of patients with end-stage renal disease are malnourished [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/1-10\">",
"     1-10",
"    </a>",
"    ], a complication that appears to be associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link&amp;anchor=H20#H20\">",
"     \"Patient survival and maintenance dialysis\", section on 'Malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of the frequency of malnutrition, periodic assessment of nutritional status should be part of the routine care of dialysis patients to permit early recognition and the institution of appropriate therapy (",
"    <a class=\"graphic graphic_table graphicRef72365 \" href=\"UTD.htm?16/9/16539\">",
"     table 1",
"    </a>",
"    ). Most of the standard methods of assessing nutritional status can be applied to patients with renal failure; however, some of these parameters are altered by uremia. It is therefore helpful to review briefly the characteristics of the different tests that are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODS OF ASSESSING NUTRITIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single measurement that can be used to determine the presence of malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, a panel of measurements is recommended, including measures of body mass (body mass index) and composition, a measure of dietary protein and energy intake, and at least one measure of serum protein status (",
"    <a class=\"graphic graphic_table graphicRef67264 \" href=\"UTD.htm?42/23/43388\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination can often provide important clues to the patient who might be malnourished. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms such as nausea, vomiting, anorexia, or weight loss or gain. Large interdialytic weight gain is discouraged because it is thought to reflect excessive fluid and sodium intake. In some cases, however, over time, increased body weight gain may represent improved nutritional status [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/13\">",
"       13",
"      </a>",
"      ]. A careful assessment should be performed to distinguish between these possibilities.",
"     </li>",
"     <li>",
"      The presence of concomitant problems that can affect nutrition, such as alcoholism, diabetes mellitus, and gastrointestinal disease.",
"     </li>",
"     <li>",
"      Psychosocial issues such as access and affordability of food, ability to prepare meals, and the role of family members in food preparation. Signs or symptoms of depression should also be identified, since clinical depression often results in a disinterest and decrease in caloric intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination should include an assessment of the patient's volume status, as it is the patient's \"dry weight\" which should be compared to the recommended body weight. The percentage change (if any) of the \"dry weight\" should also be assessed approximately every month [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Food intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate assessment of the patient's food intake is an important component of the nutritional assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/15\">",
"     15",
"    </a>",
"    ]. This should be performed every six months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient recall should cover a relatively short period of time, such as 3 days, and should include dialysis and nondialysis days. A food diary is very useful, especially if the patient weighs the portions of food. The intake of protein, fat and carbohydrate can then be calculated from standard food tables. Dietary protein intake can also be estimated by calculating the protein catabolic rate (PCR), also called the protein equivalent of nitrogen appearance (nPNA), utilizing kinetic modeling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. It should be noted, however, that the PCR is a reflection of protein intake only if the patient is in neutral nitrogen balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anthropometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthropometric measurements provide a rapid, noninvasive, and reproducible method for evaluating body fat and muscle mass. This test can be easily performed by the dietitian. Body fat is estimated by measuring skin fold thickness at the triceps or subscapular area, while mid-arm circumference can provide an estimate of the muscle mass. The results of these measurements are compared to reference standards obtained from healthy adults during the National Health and Nutrition Examination Surveys (NHANES II) from 1976 to 1980 (",
"    <a class=\"graphic graphic_table graphicRef80510 \" href=\"UTD.htm?29/9/29851\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A multicenter cooperative study was undertaken to establish anthropometric norms for the dialysis population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/17\">",
"     17",
"    </a>",
"    ]. Stringent selection criteria were utilized to ensure that only stable maintenance dialysis patients were included in the study. Measurements in men (including diabetics) and in most diabetic women did not differ significantly from the NHANES II data for normal subjects. There were, however, two groups of women in whom the values were below normal: nondiabetics; and black diabetics over the age of 55 who had lower triceps skinfold thickness. Measurements in patients treated with continuous ambulatory peritoneal dialysis were similar to those of hemodialysis patients.",
"   </p>",
"   <p>",
"    These norms in relatively \"healthy\" dialysis patients allow all patients to be evaluated. As a general rule, measurements above 95 percent of normal are considered to represent adequate nutrition; values between 70 and 95 percent identify patients at risk for malnutrition; and values below 70 percent reflect significant malnutrition.",
"   </p>",
"   <p>",
"    While anthropometry has the advantage of being simple and quick to carry out, it is not as accurate as more sophisticated techniques. It is best if serial measurements are carried out by the same observer. If this isn't feasible, it somewhat limits its usefulness. More sophisticated measures of body composition include bioelectric impedance analysis (BIA) and dual-energy x-ray absorptiometry (DEXA) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ]. A major drawback of these techniques is the difficulty in distinguishing between fat mass and body water. In addition, DEXA is fairly expensive and not always readily available.",
"   </p>",
"   <p>",
"    One study compared five body composition techniques in patients treated with peritoneal dialysis: BIA, DEXA, total-body potassium counting, and anthropometry by two methods [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/20\">",
"     20",
"    </a>",
"    ]. The patients were compared to age and sex matched healthy subjects. Significant differences were noted between men and women (with women having a higher percentage of body fat) but there were no differences between control subjects and dialysis patients. Although there were also significant differences between the body composition techniques, there was good correlation between the techniques and the authors concluded that each could be readily used in stable dialysis patients.",
"   </p>",
"   <p>",
"    At present, anthropometry is the only method that can be readily performed in most units. BIA or DEXA should be reserved for selected patients.",
"   </p>",
"   <p>",
"    Energy expenditure may be also estimated with a device that uses sensors to continuously monitor body movement, heat flux, and skin temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/12,21\">",
"     12,21",
"    </a>",
"    ]. This device is not used in clinical practice, but may provide information that can be used in the assessment of nutrient intake for individual patients, as well as a research tool [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Plasma protein measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of several circulating proteins has been used to assess nutritional status in patients with normal renal function. The same proteins can be monitored in end-stage renal disease (",
"    <a class=\"graphic graphic_table graphicRef64694 \" href=\"UTD.htm?15/51/16187\">",
"     table 4",
"    </a>",
"    ). There are, however, potential limitations to their use in this setting due to changes in protein distribution or metabolism by renal failure or comorbid conditions. As a result, interpretation of the values obtained should be undertaken with caution (",
"    <a class=\"graphic graphic_table graphicRef79593 \" href=\"UTD.htm?6/46/6891\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma albumin concentration correlates reasonably well with body protein stores; hypoalbuminemia is a relatively late manifestation of malnutrition, since albumin has a long half-life and hepatic synthetic reserve is very large. However, changes in extracellular volume represent a potential source of error in assessing the plasma albumin concentration. As an example, volume expansion, which is usually present before dialysis, will lower the plasma albumin concentration by dilution.",
"   </p>",
"   <p>",
"    Several studies have demonstrated a negative correlation between the plasma albumin concentration and mortality in patients undergoing maintenance hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/8,9,22-24\">",
"     8,9,22-24",
"    </a>",
"    ]. The increase in mortality with hypoalbuminemia appears to occur even at near normal albumin levels (3.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or 35",
"    <span class=\"nowrap\">",
"     g/L);",
"    </span>",
"    however, the risk is greater with more severe hypoalbuminemia, being greatest in patients with a plasma albumin concentration below 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef70749 \" href=\"UTD.htm?19/37/20061\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/8\">",
"     8",
"    </a>",
"    ]. A serum albumin concentration less than 3.8",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    suggests a diagnosis of protein-energy wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to appreciate that hypoalbuminemia is not necessarily synonymous with malnutrition or underdialysis. As an example, in one study of 841 dialysis patients, serum albumin correlated only weakly with poor nutritional status as indicated by a subjective global assessment score &gt;1, lean body mass, body mass index and hand grip strength [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/25\">",
"     25",
"    </a>",
"    ]. The subjective global assessment score used in this study includes three patient-reported components (weight loss, appetite, and vomiting) and three evaluator-performed components (muscle wasting, presence of edema, and loss of subcutaneous fat).",
"   </p>",
"   <p>",
"    Some patients treated with maintenance dialysis have a low plasma albumin concentration due to decreased albumin synthesis despite apparently adequate dialysis and protein intake [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. These patients have evidence of an acute phase response, suggesting that an underlying inflammatory process is responsible for the decline in albumin production. In the cross-sectional study cited above, among patients with normal nutritional status, serum albumin negatively correlated with the inflammatory marker, C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/25\">",
"     25",
"    </a>",
"    ]. Inflammation could be due in part to the use of bioincompatible dialysis membranes, underlying access infections, or other occult infections or inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical practice guidelines for nutrition among dialysis patients were published by a working group for the National Kidney Foundation Dialysis Outcome Quality Initiative (DOQI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/14\">",
"     14",
"    </a>",
"    ]. They recommended that the serum albumin concentration (obtained either predialysis or when stable) should be measured monthly (see below). The BCG method for measurement has been recommended. In the 2009 USRDS Annual Report, the mean serum albumin level of incident dialysis patients in the United States was 3.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (31",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    This value has been unchanged since 1998 when the mean serum albumin for incident dialysis patients in the United States was 3.2",
"    <span class=\"nowrap\">",
"     g/L,",
"    </span>",
"    thus representing a 0.1",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    decline [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Transferrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma transferrin concentration is commonly used to assess nutritional status in subjects with normal renal function. Low transferrin levels have been described in dialysis patients and have been ascribed to malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, plasma transferrin values are frequently reduced in renal failure independent of malnutrition, perhaps due to fluctuations in iron stores [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/30\">",
"     30",
"    </a>",
"    ]. This is a frequent problem following the initiation of erythropoietin therapy for the treatment of uremic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prealbumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma concentration of prealbumin (transthyretin) also may vary with the state of nutrition in patients with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/31\">",
"     31",
"    </a>",
"    ]. However, this protein is normally excreted and metabolized by the kidney and tends to accumulate in renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, a single value may not be a very accurate predictor of nutrition. However, serial measurements can be monitored once a",
"    <strong>",
"     baseline level",
"    </strong>",
"    has been established for the individual patient.",
"   </p>",
"   <p>",
"    The plasma prealbumin concentration can be used to assess the response to nutritional interventions begun for presumed malnutrition. Prealbumin, unlike albumin, has a short half-life and changes rapidly in response to alterations in nutritional status. It has been suggested that a value below 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is indicative of malnutrition in the patients on maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Although this hypothesis has not been systematically studied, it is appropriate to monitor the serum prealbumin concentration and to presume that a decline in the serum level may be related to inadequate nutrition.",
"   </p>",
"   <p>",
"    However, lower prealbumin levels, like those of albumin, may also reflect an acute intercurrent illness. One study also found that decreased prealbumin levels correlated independently with increased mortality and hospitalization due to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Amino acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variable plasma amino acid pattern in end-stage renal disease. In general, the essential amino acid levels are decreased, while the nonessential amino acids are either within the normal range or increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/30,34\">",
"     30,34",
"    </a>",
"    ]. As an example, phenylalanine is decreased and tyrosine is usually normal or elevated in renal failure, resulting in a decreased phenylalanine-to-tyrosine ratio. The same relationship exists for valine and glycine and for the ratio of essential to nonessential amino acids. These changes are seen in almost all patients and may therefore be due to uremia itself, rather than reflecting malnutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Plasma cholesterol concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma cholesterol concentration is reduced in malnourished patients with normal renal function. Cholesterol levels are also lower in those with end-stage renal disease. In this setting, there is an inverse relationship between mortality and the cholesterol concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/9,35,36\">",
"     9,35,36",
"    </a>",
"    ]. A serum cholesterol less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    suggests the presence of protein-energy wasting among hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link&amp;anchor=H14#H14\">",
"     \"Inflammation in renal insufficiency\", section on 'Does inflammation lead to malnutrition?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blood urea nitrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial measurements of the BUN may be particularly helpful in monitoring protein intake and nutritional status. Malnourished patients often show a gradual reduction in BUN and become wasted. Low predialysis BUN levels have also been associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/16\">",
"     16",
"    </a>",
"    ]. If decreased intake is not considered, the fall in BUN may lead to a reduction in dialysis prescription. This in turn may worsen the malnutrition as underdialysis leads to anorexia and a further decline in protein intake. It is for this reason that protein catabolic rate is monitored in dialysis patients, since this parameter can estimate protein intake in the stable patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Creatinine production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since creatinine is produced from nonenzymatic creatine metabolism in skeletal muscle, estimating the rate of creatinine production has been used to assess lean body mass in stable patients on maintenance dialysis. Estimated lean body mass was below normal in 47 and 66 percent of hemodialysis and peritoneal dialysis patients, a presumed reflection of inadequate nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/4\">",
"     4",
"    </a>",
"    ]. There was a significant correlation between lean body mass and the plasma albumin concentration in the group as a whole; however, there was substantial variability in individual patients. Survival is reduced in patients with lower plasma creatinine concentrations, another suggestion of the impact of nutritional status on patient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/9,23,24\">",
"     9,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no one measure which can be used in any patient population to accurately assess nutritional status. This is particularly true in renal failure which can alter the plasma levels of some of the parameters used to estimate nutrition (",
"    <a class=\"graphic graphic_table graphicRef79593 \" href=\"UTD.htm?6/46/6891\">",
"     table 5",
"    </a>",
"    ). Criteria that may be used for the diagnosis of protein-energy wasting include a serum albumin of less than 3.8",
"    <span class=\"nowrap\">",
"     g/L,",
"    </span>",
"    serum pre-albumin of less than 30",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and a serum cholesterol less than 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    A number of measures of body mass, such as BMI, anthropometry, and dietary protein and energy intake may also be used to identify the presence of protein-energy wasting.",
"   </p>",
"   <p>",
"    Thus, patients with end-stage renal disease, like other patients, should undergo a variety of measurements to develop a profile that can be used to detect the possible development of malnutrition. The NKF-DOQI clinical practice guidelines for nutrition in chronic renal failure addresses the appropriate panels of measures that are useful in the regular assessment of nutritional status in patients treated with maintenance dialysis, as well as those ancillary measurements that may be indicated under special circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, we perform careful anthropometric measurements which are compared to tables of normal subjects and those with end-stage renal disease matched for sex, age, and height (",
"    <a class=\"graphic graphic_table graphicRef80510 \" href=\"UTD.htm?29/9/29851\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with reduced anthropometry can be classified as to the degree of wasting by comparing the percent decline compared to expected values. We also monitor the plasma proteins noted above to provide a more complete picture of nutritional status and, with",
"    <strong>",
"     serial measurements",
"    </strong>",
"    , to determine whether there has been a change in nutritional status.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The plasma albumin concentration should be measured monthly after the patient has stabilized on dialysis and reached the estimated dry weight [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15399/abstract/14\">",
"       14",
"      </a>",
"      ]. If the plasma albumin concentration is reduced to less than 3.8",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"      after stabilization, the dietary protein intake should be assessed, and if low, an increase in protein intake should be instituted. If hypoalbuminemia continues, a search for a previously unidentified acute inflammatory illness should be undertaken. Although the level of the C-reactive protein may be helpful in elucidating the presence of an acute inflammatory state, it does not indicate the cause.",
"     </li>",
"     <li>",
"      Plasma transferrin is useful if iron stores are also assessed and determined to be normal.",
"     </li>",
"     <li>",
"      Prealbumin is helpful in assessing the response to a nutritional intervention and to further confirm the presence of malnutrition. A baseline value should be established. A subsequent reduction indicates the patient is at risk for malnutrition, while an increase after nutritional intervention presumably reflects a positive response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H628013028\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 to 70 percent of patients with end-stage renal disease are malnourished. The periodic assessment of nutritional status should be part of the routine care of dialysis patients to permit early recognition and the institution of appropriate therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no single measurement that can be used to determine the presence of malnutrition. We suggest using measures of body mass (body mass index) and composition, a measure of dietary protein and energy intake, and at least one measure of serum protein status. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Methods of assessing nutritional status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria that may be used for the diagnosis of protein-energy wasting include a serum albumin of less than 3.8",
"      <span class=\"nowrap\">",
"       g/L,",
"      </span>",
"      serum pre-albumin of less than 30",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and a serum cholesterol less than 100",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      A number of measures of body mass, such as BMI, anthropometry, and dietary protein and energy intake may also be used to identify the presence of protein-energy wasting. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/1\">",
"      Thunberg BJ, Swamy AP, Cestero RV. Cross-sectional and longitudinal nutritional measurements in maintenance hemodialysis patients. Am J Clin Nutr 1981; 34:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/2\">",
"      Wolfson M, Strong CJ, Minturn D, et al. Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 1984; 39:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/3\">",
"      Schoenfeld PY, Henry RR, Laird NM, Roxe DM. Assessment of nutritional status of the National Cooperative Dialysis Study population. Kidney Int Suppl 1983; :S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/4\">",
"      Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/5\">",
"      Marckmann P. Nutritional status of patients on hemodialysis and peritoneal dialysis. Clin Nephrol 1988; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/6\">",
"      Buchwald R, Pe&ntilde;a JC. Evaluation of nutritional status in patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/7\">",
"      Young GA, Kopple JD, Lindholm B, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/8\">",
"      Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/9\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/10\">",
"      Aparicio M, Cano N, Chauveau P, et al. Nutritional status of haemodialysis patients: a French national cooperative study. French Study Group for Nutrition in Dialysis. Nephrol Dial Transplant 1999; 14:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/11\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/12\">",
"      Fouque D, Pelletier S, Mafra D, Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011; 80:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/13\">",
"      Testa A, Beaud JM. The other side of the coin: interdialytic weight gain as an index of good nutrition. Am J Kidney Dis 1998; 31:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/14\">",
"      Dialysis Outcomes Quality Initiative Guidelines. Clinical practice guidelines for nutrition in chronic renal failure. I. Adult guidelines A. Maintenance dialysis. Am J Kidney Dis 2000; 35(Suppl 2):S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/15\">",
"      Wolfson M. Management of protein and energy intake in dialysis patients. J Am Soc Nephrol 1999; 10:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/16\">",
"      Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/17\">",
"      Nelson EE, Hong CD, Pesce AL, et al. Anthropometric norms for the dialysis population. Am J Kidney Dis 1990; 16:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/18\">",
"      VanItallie TB, Yang MU, Heymsfield SB, et al. Height-normalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr 1990; 52:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/19\">",
"      Segal KR, Burastero S, Chun A, et al. Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement. Am J Clin Nutr 1991; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/20\">",
"      Stall SH, Ginsberg NS, DeVita MV, et al. Comparison of five body-composition methods in peritoneal dialysis patients. Am J Clin Nutr 1996; 64:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/21\">",
"      Mafra D, Deleaval P, Teta D, et al. Influence of inflammation on total energy expenditure in hemodialysis patients. J Ren Nutr 2011; 21:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/22\">",
"      Goldwasser P, Mittman N, Antignani A, et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 1993; 3:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/23\">",
"      Teehan BP, Schleifer CR, Brown JM, et al. Urea kinetic analysis and clinical outcome on CAPD. A five year longitudinal study. Adv Perit Dial 1990; 6:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/24\">",
"      Rocco MV, Jordan JR, Burkart JM. The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 1993; 4:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/25\">",
"      Gama-Axelsson T, Heimb&uuml;rger O, Stenvinkel P, et al. Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol 2012; 7:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/26\">",
"      Kaysen GA, Rathore V, Shearer GC, Depner TA. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/27\">",
"      Rocco MV, Dwyer JT, Larive B, et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/28\">",
"      Tayeb JS, Provenzano R, El-Ghoroury M, et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis 2000; 35:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/29\">",
"      US Renal Data System. USRDS 2009 Annual Data Report. ESRD clinical performance measures project. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/30\">",
"      Kopple JD, Swendseid ME. Vitamin nutrition in patients undergoing maintenance hemodialysis. Kidney Int Suppl 1975; :79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/31\">",
"      Chertow GM, Ackert K, Lew NL, et al. Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 2000; 58:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/32\">",
"      Cano N, Di Costanzo-Dufetel J, Calaf R, et al. Prealbumin-retinol-binding-protein-retinol complex in hemodialysis patients. Am J Clin Nutr 1988; 47:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/33\">",
"      Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA. Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int 2005; 68:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/34\">",
"      Bergstr&ouml;m J, Alvestrand A, F&uuml;rst P. Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int 1990; 38:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/35\">",
"      Degoulet P, Legrain M, R&eacute;ach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15399/abstract/36\">",
"      Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61:1887.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1850 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15399=[""].join("\n");
var outline_f15_2_15399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H628013028\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODS OF ASSESSING NUTRITIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Food intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anthropometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Plasma protein measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Albumin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Transferrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prealbumin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Amino acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Plasma cholesterol concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blood urea nitrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Creatinine production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H628013028\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1850|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/37/20061\" title=\"figure 1\">",
"      Risk of mortality among hemodial pts according to serum albumin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/9/16539\" title=\"table 1\">",
"      Signs malnutrition HD patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/23/43388\" title=\"table 2\">",
"      Criteria for protein-energy wasting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/9/29851\" title=\"table 3\">",
"      Anthropometry in HD patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/51/16187\" title=\"table 4\">",
"      Estimates of nutritional status in HD pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/46/6891\" title=\"table 5\">",
"      Pitfalls with plasma proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15400="Preoperative evaluation for lung resection";
var content_f15_2_15400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preoperative evaluation for lung resection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15400/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15400/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15400/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15400/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/2/15400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is currently the leading cause of cancer death in the United States, accounting for about 159,480 deaths per year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical resection remains the only potentially curative therapy for patients with localized non&ndash;small cell lung cancer (NSCLC). Due to the shared risk factor from tobacco smoking for both lung cancer and chronic obstructive pulmonary disease (COPD), however, the clinician is often faced with contemplating surgical resection in patients with impaired pulmonary function and an increased risk for lung resection.",
"   </p>",
"   <p>",
"    Ever since Graham and Singer's report in 1933 of the first successful pneumonectomy for the treatment of lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/2\">",
"     2",
"    </a>",
"    ], the search has been ongoing for the ideal preoperative test to identify those patients at greatest risk for postoperative complications. Based on the assumption that a level of pulmonary impairment exists beyond which the risk of surgical intervention is prohibitive, efforts have been wide-ranging to identify the best predictive tests and to define the threshold values necessary for minimizing surgical risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suggested tests have included measurement of preoperative pulmonary function, calculation of predicted postoperative (postresectional) pulmonary function, measures of gas exchange, and exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/5\">",
"     5",
"    </a>",
"    ]. The utility of each of these tests and a recommended approach will be presented here. General concepts of the preoperative pulmonary assessment and specific issues regarding lung cancer staging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The correlation between impaired respiratory functional status and surgical outcome following pulmonary resection was first noted in 1955 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequent studies have confirmed the value of spirometry and diffusing capacity (DLCO) in providing an accurate assessment of operative risk for lung resection via thoracotomy. However, the predictive value of forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) and DLCO for pulmonary complications is less clear when lobectomy is performed via thoracoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of patients undergoing lung resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracoplasty for pulmonary tuberculosis, patients with maximal voluntary ventilation (MVV, measured as the maximal amount a patient can inhale and exhale over 12 seconds) less than 50 percent and a forced vital capacity (FVC) less than 70 percent of predicted had a 40 percent mortality following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/6\">",
"     6",
"    </a>",
"    ]. Other studies have validated that a reduced preoperative MVV is associated with an increased risk of preoperative complications, and a threshold value of 50 percent of predicted is generally used to predict increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MVV represents an integrated test that takes into account both airflow and muscle strength. However, its strong dependence on patient effort has led to its removal from most standard pulmonary function testing, and it is now rarely used for preoperative evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) has become the primary spirometric value used for preoperative assessment. The FEV",
"    <sub>",
"     1",
"    </sub>",
"    correlates well with the degree of respiratory impairment in patients with COPD, and it provides an indirect measure of pulmonary reserve. In studies evaluating a variety of preoperative spirometric values, a reduced preoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    (&lt;60 percent predicted) was the strongest predictor of postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diffusing capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of DLCO in predicting postoperative complications following pulmonary resection has also been evaluated. Retrospective studies have reported that actual DLCO (as a percent of the predicted value) and predicted postoperative DLCO are the most important predictors of mortality and postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Current guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American College of Chest Physicians and the British Thoracic Society suggest that patients with a preoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    in excess of 2 L (or &gt;80 percent predicted) generally tolerate pneumonectomy, whereas those with a preoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    greater than 1.5 L tolerate lobectomy (",
"    <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/4,20,21\">",
"     4,20,21",
"    </a>",
"    ]. However, if there is either undue exertional dyspnea or coexistent interstitial lung disease, then measurement of DLCO should also be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with preoperative results for FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO that are both &gt;80 percent predicted do not need further physiological testing.",
"   </p>",
"   <p>",
"    Although pulmonary function that is better than the aforementioned threshold levels predicts a good surgical outcome, it has been difficult to identify a single absolute value of preoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    below which the risk of surgical intervention should be considered prohibitive for all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/22\">",
"     22",
"    </a>",
"    ]. Responsible factors for this lack of a single value include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differences in the amount of lung tissue to be resected, as the extent of the planned resection will affect the choice of an acceptable preoperative FEV",
"      <sub>",
"       1",
"      </sub>",
"      .",
"     </li>",
"     <li>",
"      Differences in the severity of underlying lung disease and the contribution to total lung function of the portion of lung to be resected.",
"     </li>",
"     <li>",
"      Differences in size, age, gender, and race of patients undergoing lung resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, most studies used as the basis of current guidelines were published prior to 1990, and supportive care and perioperative management have improved substantially since that time. This could result in an overly restrictive approach to surgical therapy. As an example, a retrospective analysis of 150 patients treated at a single center between 2001 and 2003 found that a cutoff preoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    value of 47 percent resulted in the greatest diagnostic accuracy in predicting ability to survive pulmonary resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/23\">",
"     23",
"    </a>",
"    ]. The authors suggested that a lower threshold of predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    (45 to 50 percent predicted) could be accepted without increased mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREDICTED POSTOPERATIVE PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not clearly fall into a low risk category based upon the preoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO criteria mentioned above (each &gt;80 percent predicted) should undergo further testing to allow calculation of predicted postoperative lung function. Predicted postoperative values for FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO should take into account the preoperative values, the amount of lung tissue to be resected, and its contribution to overall function.",
"   </p>",
"   <p>",
"    In one study that has been heavily cited, a predicted postpneumonectomy FEV",
"    <sub>",
"     1",
"    </sub>",
"    greater than 0.8 L was chosen as the threshold value [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/24\">",
"     24",
"    </a>",
"    ]. Prediction of postoperative pulmonary function was based upon a combination of spirometry and quantitative perfusion lung scanning to estimate the degree of functional loss following surgery. Because it may be difficult to predict before the time of surgery whether the patient will need a pneumonectomy, the authors used the calculated function in the entire noncancerous lung (ie, the lung that would remain if a pneumonectomy needed to be performed) as a criterion for surgical candidacy.",
"   </p>",
"   <p>",
"    Radionuclide lung scanning can help predict postoperative lung function following resection, taking into account preoperative spirometry and the fractional predicted loss of lung function demonstrated by preoperative scanning. In one study, the correlation between predicted postoperative lung function and observed postoperative lung function was particularly good (and stable over time) following pneumonectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/25\">",
"     25",
"    </a>",
"    ]. However, following lobectomy, there was a disproportionate early loss in observed function (compared to the predicted loss), followed by significant functional improvement over time.",
"   </p>",
"   <p>",
"    Numerical cutoffs for predicted postoperative lung function have also been based upon the percentage of predicted value rather than the absolute level of predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/5,20,21,26\">",
"     5,20,21,26",
"    </a>",
"    ]. Predicted postoperative function is calculated using preoperative values of FEV",
"    <sub>",
"     1",
"    </sub>",
"    or DLCO and measurement of lobar or whole lung fractional contribution to function as determined by quantitative perfusion lung scanning, ventilation, or CT lung scanning. Alternatively, the estimated postoperative (ePO) FEV",
"    <sub>",
"     1",
"    </sub>",
"    is calculated by the formula: ePO FEV",
"    <sub>",
"     1",
"    </sub>",
"    = preop FEV",
"    <sub>",
"     1",
"    </sub>",
"    x (number of segments remaining",
"    <span class=\"nowrap\">",
"     postoperatively/total",
"    </span>",
"    number of lung segments [normally 18]) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/27\">",
"     27",
"    </a>",
"    ]. The value obtained is then compared to the predicted value for FEV",
"    <sub>",
"     1",
"    </sub>",
"    for that individual&rsquo;s height, age, and gender to obtain the percent predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    . In one study, a predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    that was 40 percent or more of the predicted normal value for that patient was associated with no postoperative mortality (in 47 patients), whereas a value less than 40 percent was associated with 50 percent mortality (in six patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/26\">",
"     26",
"    </a>",
"    ]. A subsequent study confirmed the correlation of predicted postoperative value of FEV",
"    <sub>",
"     1",
"    </sub>",
"    with the likelihood of postoperative complications in patients undergoing lung resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/28\">",
"     28",
"    </a>",
"    ]. The odds ratio for complications was 1.46 for each 0.2 L decrease in predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    Other reports have investigated the value of the predicted postoperative DLCO based upon the preoperative value and an assessment of regional lung function by quantitative perfusion scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. In one such study, high morbidity and mortality were associated with a predicted postoperative DLCO below 40 percent of the predicted normal value [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/5,26\">",
"     5,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Current guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American College of Chest Physicians consider a patient to be at increased risk for lung resection with predicted postoperative values for either FEV",
"    <sub>",
"     1",
"    </sub>",
"    or DLCO &lt;40 percent predicted (",
"    <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21\">",
"     21",
"    </a>",
"    ]. Preoperative exercise testing is recommended for patients with either of these criteria to further assess their surgical risk. Patients with a predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;30 percent predicted or a value &lt;1650 for the product of predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    and predicted postoperative DLCO (each expressed as percent predicted) are particularly singled out for their risk of perioperative death and cardiopulmonary complications; they should be counseled about non-standard surgical options and non-operative treatment modalities in preference to standard lung resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the European Respiratory Society and the European Society of Thoracic Surgery",
"    <span class=\"nowrap\">",
"     (ERS/ESTS)",
"    </span>",
"    advise that the cutoff value for predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    or DLCO may be lowered to 30 percent rather than 40 percent, due to improvements in surgical technique and the belief that removal of hyperinflated, poorly functioning lung tissue during surgery ameliorates the calculated loss in lung function through a &ldquo;lung volume reduction effect&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"     30",
"    </a>",
"    ]. However, evaluation with cardiopulmonary exercise testing (CPET) is needed prior to making a final decision on operability. (For a figure showing the",
"    <span class=\"nowrap\">",
"     ERS/ESTS",
"    </span>",
"    algorithm, please see Figure 2 in the guidelines at",
"    <a class=\"external\" href=\"file://erj.ersjournals.com/content/34/3/782.full.pdf+html\">",
"     file://erj.ersjournals.com/content/34/3/782.full.pdf+html",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Concomitant volume reduction surgery'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Integrated cardiopulmonary exercise testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF GAS EXCHANGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although spirometric values, most notably the FEV",
"    <sub>",
"     1",
"    </sub>",
"    , correlate with the severity of COPD, they do not provide direct information regarding the degree of gas exchange impairment that is often present, which may be measured directly by arterial blood gases. However, arterial blood gases have not proved to be as useful as measurement of FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO in assessing suitability for lung resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arterial PO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline (resting) arterial PO",
"    <sub>",
"     2",
"    </sub>",
"    is probably not an important predictor of postoperative complications or mortality following pulmonary resection. When there is partial or complete endobronchial obstruction in a region of lung that is to be resected, ventilation-perfusion matching and therefore resting arterial PO",
"    <sub>",
"     2",
"    </sub>",
"    may actually",
"    <strong>",
"     improve",
"    </strong>",
"    following pulmonary resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arterial PCO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercapnia (arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    greater than 45 mmHg) has traditionally been considered a significant risk factor for pulmonary resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/32\">",
"     32",
"    </a>",
"    ]. However, this hypothesis has never been proven, and a 1994 study showed no difference in postoperative complications between patients with a preoperative PCO",
"    <sub>",
"     2",
"    </sub>",
"    less than 45 mmHg and those with a preoperative PCO",
"    <sub>",
"     2",
"    </sub>",
"    of 45 mmHg or higher (17 versus 13 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/28,33\">",
"     28,33",
"    </a>",
"    ]. Thus, hypercapnia per se is not a contraindication to surgery, although surgery is frequently precluded in hypercapnic patients because of a low predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    or poor exercise performance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXERCISE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of preoperative exercise testing in the evaluation of patients prior to thoracotomy has evolved significantly over the past few decades [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/34\">",
"     34",
"    </a>",
"    ]. As a comprehensive physiologic evaluation, a patient's performance on exercise testing is dependent upon the interactions among pulmonary function, cardiovascular function, and oxygen utilization by peripheral tissues. Exercise testing can take many forms, ranging from stair climbing to complete cardiopulmonary exercise testing with measurement of anaerobic threshold, oxygen consumption, and the level of work achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stair climbing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years, surgeons have utilized stair climbing as a preoperative screening tool. Though poorly standardized, this form of testing has been shown to identify patients at increased risk for lung resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective series of 640 lobectomy and pneumonectomy candidates, attainment of a lower altitude (less than 12 meters) on a symptom-limited stair climbing test was associated with increased cardiopulmonary complications, mortality, and cost, compared with climbing to a higher altitude (22 meters) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective series of 160 patients studied one day prior to lung resection found that those who were able to climb more than eight flights of stairs, at their own pace, were less likely to experience complications than those who could climb fewer than seven flights of stairs (6.5 versus 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/37\">",
"       37",
"      </a>",
"      ]. Patients who climbed between seven and eight flights of stairs had an intermediate risk of complications (30 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Integrated cardiopulmonary exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guidelines of the American College of Chest Physicians (ACCP) (",
"    <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"     algorithm 1",
"    </a>",
"    ) and those of the European Respiratory Society and the European Society of Thoracic Surgery",
"    <span class=\"nowrap\">",
"     (ERS/ESTS)",
"    </span>",
"    differ slightly in the exact timing and indications for cardiopulmonary exercise testing (CPET) in the evaluation of a patient for potential lung resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21,30\">",
"     21,30",
"    </a>",
"    ]. (For a figure showing the",
"    <span class=\"nowrap\">",
"     ERS/ESTS",
"    </span>",
"    algorithm, please see Figure 2 in the guidelines at",
"    <a class=\"external\" href=\"file://erj.ersjournals.com/content/34/3/782.full.pdf+html\">",
"     file://erj.ersjournals.com/content/34/3/782.full.pdf+html",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important measurement during cardiopulmonary exercise testing that correlates with postoperative complications is the level of work achieved, as measured by maximal oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    max); invasive hemodynamic measurements during exercise provide little additional useful data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/41\">",
"     41",
"    </a>",
"    ]. An early report demonstrated no mortality in patients able to achieve a VO",
"    <sub>",
"     2",
"    </sub>",
"    max in excess of 1",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    compared with 75 percent mortality in those with a VO",
"    <sub>",
"     2",
"    </sub>",
"    max below 1",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expressing VO",
"    <sub>",
"     2",
"    </sub>",
"    max in terms of",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min, which takes into account the patient's body mass, may increase the predictive power of the test. One study, for example, found that only one of 10 patients able to achieve a VO",
"    <sub>",
"     2",
"    </sub>",
"    max greater than 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min had a postoperative complication, whereas all six patients with a VO",
"    <sub>",
"     2",
"    </sub>",
"    max below 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min experienced a postoperative complication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/43\">",
"     43",
"    </a>",
"    ]. Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/5,44,45\">",
"     5,44,45",
"    </a>",
"    ]. As an example, 20 patients who were considered to be at high risk for resection by standard criteria, but who had a VO",
"    <sub>",
"     2",
"    </sub>",
"    max of 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min or greater, survived surgery and had an acceptable postoperative complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients with VO",
"    <sub>",
"     2",
"    </sub>",
"    max &lt;10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min are at very high risk for perioperative complications and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21,45,46\">",
"     21,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VO",
"    <sub>",
"     2",
"    </sub>",
"    max can also be expressed as a percentage of the predicted value. One report found that a VO",
"    <sub>",
"     2",
"    </sub>",
"    max &lt;43 percent of predicted was associated with a 90 percent probability of developing serious postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/47\">",
"     47",
"    </a>",
"    ]. A cutoff value below 60 percent predicted was thought to be prohibitive for resections involving more than one lobe, whereas a value above 75 percent predicted suggested a good outcome, regardless of the extent of resection. Two subsequent studies, including a total of 280 patients with potentially operable lung cancer, also noted increased mortality among those with VO",
"    <sub>",
"     2",
"    </sub>",
"    max &lt;50 percent of predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Current guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Chest Physicians considers patients with VO",
"    <sub>",
"     2",
"    </sub>",
"    max &lt;10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min, or those with VO",
"    <sub>",
"     2",
"    </sub>",
"    max &lt;15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min and both predicted postoperative FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO &lt;40 percent predicted, to be at high risk for perioperative death and cardiopulmonary complications (",
"    <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21\">",
"     21",
"    </a>",
"    ]. Guidelines from the European Respiratory Society and the European Society of Thoracic Surgery",
"    <span class=\"nowrap\">",
"     (ERS/ESTS)",
"    </span>",
"    similarly consider surgery to be contraindicated for patients with a VO",
"    <sub>",
"     2",
"    </sub>",
"    max &lt;10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min or &lt;35 percent predicted, whereas patients with VO",
"    <sub>",
"     2",
"    </sub>",
"    max &gt;20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min or &gt;75 percent predicted are deemed to be operable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"     30",
"    </a>",
"    ]. Further evaluation is recommended for individuals with VO",
"    <sub>",
"     2",
"    </sub>",
"    max results between these two levels. (For a figure showing the",
"    <span class=\"nowrap\">",
"     ERS/ESTS",
"    </span>",
"    algorithm, please see Figure 2 in the guidelines at",
"    <a class=\"external\" href=\"file://erj.ersjournals.com/content/34/3/782.full.pdf+html\">",
"     file://erj.ersjournals.com/content/34/3/782.full.pdf+html",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For those with intermediate VO",
"    <sub>",
"     2",
"    </sub>",
"    max values (between 10 and 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min) and postoperative predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO values &ge;30 percent, resection up to the calculated extent is acceptable, according to the",
"    <span class=\"nowrap\">",
"     ERS/ESTS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"     30",
"    </a>",
"    ]. On the other hand, if either the postoperative predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    or DLCO is &lt;30 percent, the predicted postoperative (ppo) VO",
"    <sub>",
"     2",
"    </sub>",
"    max is calculated. If the ppo VO",
"    <sub>",
"     2",
"    </sub>",
"    max is &lt;10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min or &lt;35 percent, it is recommended that the patient seek nonresectional options. On the other hand, if the ppo VO",
"    <sub>",
"     2",
"    </sub>",
"    max is &ge;10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min or &ge;35 percent predicted, surgical resection is not absolutely contraindicated. However, the relatively high risk suggested by the low postoperative predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    or DLCO necessitates a shared decision-making process in which the patient fully understands the relatively high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CONCOMITANT VOLUME REDUCTION SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume reduction surgery (LVRS), now being used in carefully selected patients with advanced emphysema, may impact the resectability of lung tumors in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. Resectional surgery for lung cancer that simultaneously removes severely emphysematous lung tissue may actually improve rather than worsen lung function through increasing lung elastic recoil and diaphragmatic efficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    As an example, one series reported the results of 14 patients with severe emphysema in whom pulmonary nodules were detected during the course of preoperative evaluation for LVRS and who then underwent combined resection and LVRS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/51\">",
"     51",
"    </a>",
"    ]. One postoperative death occurred, but the FEV",
"    <sub>",
"     1",
"    </sub>",
"    significantly",
"    <strong>",
"     increased",
"    </strong>",
"    among survivors, from a mean preoperative value of 676 mL to a mean of 886 mL following the operation. Significant improvements were also seen in arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    , dyspnea index, and six-minute walk distance. Most tumors were removed by wedge resection, with only 3 of 14 patients undergoing complete lobectomy.",
"   </p>",
"   <p>",
"    The magnitude and duration of benefit of LVRS, as well as optimal patient selection criteria, have not been precisely defined. However, current clinical guidelines from the American College of Chest Physicians suggest considering combining LVRS and lung cancer resection if the cancer is in an area of upper lobe emphysema, and if the patient's FEV",
"    <sub>",
"     1",
"    </sub>",
"    and DLCO are both &gt;20 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15400/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk for lung cancer and COPD are also frequently at risk for preoperative morbidity related to coronary heart disease and may also need preoperative cardiovascular evaluation. Evaluation of cardiac risk is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the poor prognosis for patients with lung cancer that is not treated surgically, every effort should be made to identify those patients who will tolerate resection. Although the level of acceptable risk for postoperative complications is somewhat subjective, utilizing a series of widely available preoperative tests provides a method of defining a specific patient's risk. An algorithm describing the American College of Chest Physicians guidelines is provided in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"     algorithm 1",
"    </a>",
"    ). For a figure showing the",
"    <span class=\"nowrap\">",
"     ERS/ESTS",
"    </span>",
"    algorithm, please see Figure 2 in the guidelines at",
"    <a class=\"external\" href=\"file://erj.ersjournals.com/content/34/3/782.full.pdf+html\">",
"     file://erj.ersjournals.com/content/34/3/782.full.pdf+html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Given the high prevalence of COPD among patients with lung cancer, screening spirometry should be obtained in all patients prior to lung resection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with preserved lung function should tolerate resection well in the absence of other comorbid conditions, and a preoperative value of forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) &gt;2 L (or &ge;80 percent predicted) suggests that the patient should be able to tolerate pneumonectomy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Preoperative pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with preoperative FEV",
"      <sub>",
"       1",
"      </sub>",
"      &lt;2 L (or &lt;80 percent predicted), the predicted postoperative FEV",
"      <sub>",
"       1",
"      </sub>",
"      should be calculated, based upon the preoperative value and the fractional functional contribution of the lung to be resected. The fractional contribution of the lung to be resected can be estimated with quantitative perfusion, ventilation, or CT lung scanning. A predicted postoperative FEV",
"      <sub>",
"       1",
"      </sub>",
"      &gt;800 mL (&gt;40 percent predicted) suggests that the patient can undergo resection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Predicted postoperative pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a predicted postoperative FEV",
"      <sub>",
"       1",
"      </sub>",
"      &ge;30 percent but &le;40 percent, further assessment is indicated, including determination of predicted postoperative diffusing capacity (DLCO) and cardiopulmonary exercise testing (CPET), prior to making a final decision on operability (",
"      <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"       algorithm 1",
"      </a>",
"      ). A calculated postoperative predicted (ppo) DLCO value &lt;40 percent suggests a high postoperative risk, as does a value &le;1650 for the product of ppo FEV",
"      <sub>",
"       1",
"      </sub>",
"      and ppo DLCO (each expressed as percent predicted). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Predicted postoperative pulmonary function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Concomitant volume reduction surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiopulmonary exercise testing (CPET) is useful when the risk of complications is felt to be intermediate after completion of the tests outlined above. The American College of Chest Physicians suggests performing a CPET when the product of ppo FEV",
"      <sub>",
"       1",
"      </sub>",
"      and ppo DLCO is less than 1650 and either the ppo FEV",
"      <sub>",
"       1",
"      </sub>",
"      or ppo DLCO is &lt;40 percent (",
"      <a class=\"graphic graphic_algorithm graphicRef50702 \" href=\"UTD.htm?5/8/5249\">",
"       algorithm 1",
"      </a>",
"      ). The European Respiratory Society and the European Society of Thoracic Surgery",
"      <span class=\"nowrap\">",
"       (ERS/ESTS)",
"      </span>",
"      guidelines suggest a CPET in all patients with a baseline (preoperative) FEV",
"      <sub>",
"       1",
"      </sub>",
"      or DLCO &lt;80 percent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Exercise testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who can achieve a VO",
"      <sub>",
"       2",
"      </sub>",
"      max &gt;20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute (or &gt;75 percent predicted) are likely to have an acceptable rate of postoperative complications, whereas those with a value &lt;10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min (or less than 35 percent predicted) are probably best managed by nonsurgical modalities. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Current guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those with VO",
"      <sub>",
"       2",
"      </sub>",
"      max values in between 10 and 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute, the predicted postoperative (ppo) VO",
"      <sub>",
"       2",
"      </sub>",
"      max is calculated. If the ppo VO",
"      <sub>",
"       2",
"      </sub>",
"      max is &lt;10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min or &lt;35 percent, it is recommended that the patient seek nonresectional options. On the other hand, if the ppo VO",
"      <sub>",
"       2",
"      </sub>",
"      max is &ge;10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min or &ge;35 percent, resection is not absolutely contraindicated, but the patient must understand the higher risk if either the ppo FEV",
"      <sub>",
"       1",
"      </sub>",
"      or DLCO is less than 30 percent predicted. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Exercise testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Integrated cardiopulmonary exercise testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/2\">",
"      Graham, EA, Singer, JJ. Successful removal of an entire lung for carcinoma of the bronchus. JAMA 1933; 101:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/3\">",
"      Bolliger CT, Koegelenberg CF, Kendal R. Preoperative assessment for lung cancer surgery. Curr Opin Pulm Med 2005; 11:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/4\">",
"      Mazzone P. Preoperative evaluation of the lung resection candidate. Cleve Clin J Med 2012; 79 Electronic Suppl 1:eS17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/5\">",
"      Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest 2003; 123:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/6\">",
"      GAENSLER EA, CUGELL DW, LINDGREN I, et al. The role of pulmonary insufficiency in mortality and invalidism following surgery for pulmonary tuberculosis. J Thorac Surg 1955; 29:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/7\">",
"      Berry MF, Villamizar-Ortiz NR, Tong BC, et al. Pulmonary function tests do not predict pulmonary complications after thoracoscopic lobectomy. Ann Thorac Surg 2010; 89:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/8\">",
"      Boysen PG, Block AJ, Olsen GN, et al. Prospective evaluation for pneumonectomy using the 99mtechnetium quantitative perfusion lung scan. Chest 1977; 72:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/9\">",
"      Lockwood P. Lung function test results and the risk of post-thoracotomy complications. Respiration 1973; 30:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/10\">",
"      MITTMAN C. Assessment of operative risk in thoracic surgery. Am Rev Respir Dis 1961; 84:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/11\">",
"      Boushy SF, Billig DM, North LB, Helgason AH. Clinical course related to preoperative and postoperative pulmonary function in patients with bronchogenic carcinoma. Chest 1971; 59:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/12\">",
"      Colman NC, Schraufnagel DE, Rivington RN, Pardy RL. Exercise testing in evaluation of patients for lung resection. Am Rev Respir Dis 1982; 125:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/13\">",
"      Keagy BA, Lores ME, Starek PJ, et al. Elective pulmonary lobectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1985; 40:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/14\">",
"      Boysen PG, Block AJ, Moulder PV. Relationship between preoperative pulmonary function tests and complications after thoracotomy. Surg Gynecol Obstet 1981; 152:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/15\">",
"      Miller JI, Grossman GD, Hatcher CR. Pulmonary function test criteria for operability and pulmonary resection. Surg Gynecol Obstet 1981; 153:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/16\">",
"      Olsen GN, Block AJ, Swenson EW, et al. Pulmonary function evaluation of the lung resection candidate: a prospective study. Am Rev Respir Dis 1975; 111:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/17\">",
"      Ferguson MK, Little L, Rizzo L, et al. Diffusing capacity predicts morbidity and mortality after pulmonary resection. J Thorac Cardiovasc Surg 1988; 96:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/18\">",
"      Ferguson MK, Vigneswaran WT. Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease. Ann Thorac Surg 2008; 85:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/19\">",
"      Liptay MJ, Basu S, Hoaglin MC, et al. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol 2009; 100:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/20\">",
"      British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/21\">",
"      Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:161S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/22\">",
"      Linden PA, Bueno R, Colson YL, et al. Lung resection in patients with preoperative FEV1 &lt; 35% predicted. Chest 2005; 127:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/23\">",
"      Win T, Jackson A, Sharples L, et al. Relationship between pulmonary function and lung cancer surgical outcome. Eur Respir J 2005; 25:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/24\">",
"      Miller JI Jr. Physiologic evaluation of pulmonary function in the candidate for lung resection. J Thorac Cardiovasc Surg 1993; 105:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/25\">",
"      Ali MK, Mountain CF, Ewer MS, et al. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma. Chest 1980; 77:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/26\">",
"      Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989; 139:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/27\">",
"      Beckles MA, Spiro SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 2003; 123:105S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/28\">",
"      Kearney DJ, Lee TH, Reilly JJ, et al. Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest 1994; 105:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/29\">",
"      Pierce RJ, Copland JM, Sharpe K, Barter CE. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med 1994; 150:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/30\">",
"      Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/31\">",
"      Tisi GM. Preoperative evaluation of pulmonary function. Validity, indications, and benefits. Am Rev Respir Dis 1979; 119:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/32\">",
"      Dunn WF, Scanlon PD. Preoperative pulmonary function testing for patients with lung cancer. Mayo Clin Proc 1993; 68:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/33\">",
"      Marshall MC, Olsen GN. The physiologic evaluation of the lung resection candidate. Clin Chest Med 1993; 14:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/34\">",
"      Wyser C, Stulz P, Sol&egrave;r M, et al. Prospective evaluation of an algorithm for the functional assessment of lung resection candidates. Am J Respir Crit Care Med 1999; 159:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/35\">",
"      Van Nostrand D, Kjelsberg MO, Humphrey EW. Preresectional evaluation of risk from pneumonectomy. Surg Gynecol Obstet 1968; 127:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/36\">",
"      Olsen GN, Bolton JW, Weiman DS, Hornung CA. Stair climbing as an exercise test to predict the postoperative complications of lung resection. Two years' experience. Chest 1991; 99:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/37\">",
"      Brunelli A, Al Refai M, Monteverde M, et al. Stair climbing test predicts cardiopulmonary complications after lung resection. Chest 2002; 121:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/38\">",
"      Brunelli A, Refai M, Xium&eacute; F, et al. Performance at symptom-limited stair-climbing test is associated with increased cardiopulmonary complications, mortality, and costs after major lung resection. Ann Thorac Surg 2008; 86:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/39\">",
"      Brunelli A, Xium&eacute; F, Refai M, et al. Peak oxygen consumption measured during the stair-climbing test in lung resection candidates. Respiration 2010; 80:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/40\">",
"      Bernasconi M, Koegelenberg CF, von Groote-Bidlingmaier F, et al. Speed of ascent during stair climbing identifies operable lung resection candidates. Respiration 2012; 84:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/41\">",
"      Ribas J, D&iacute;az O, Barber&agrave; JA, et al. Invasive exercise testing in the evaluation of patients at high-risk for lung resection. Eur Respir J 1998; 12:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/42\">",
"      Eugene, H, Brown, SE, Light, RW, et al. Maximum oxygen consumption: A physiologic guide to pulmonary resection. Surg Forum 1982; 33:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/43\">",
"      Smith TP, Kinasewitz GT, Tucker WY, et al. Exercise capacity as a predictor of post-thoracotomy morbidity. Am Rev Respir Dis 1984; 129:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/44\">",
"      Walsh GL, Morice RC, Putnam JB Jr, et al. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. Ann Thorac Surg 1994; 58:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/45\">",
"      Brunelli A, Belardinelli R, Refai M, et al. Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection. Chest 2009; 135:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/46\">",
"      Schuurmans MM, Diacon AH, Bolliger CT. Functional evaluation before lung resection. Clin Chest Med 2002; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/47\">",
"      Bolliger CT, Jordan P, Sol&egrave;r M, et al. Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med 1995; 151:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/48\">",
"      Villani F, De Maria P, Busia A. Exercise testing as a predictor of surgical risk after pneumonectomy for bronchogenic carcinoma. Respir Med 2003; 97:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/49\">",
"      Win T, Jackson A, Sharples L, et al. Cardiopulmonary exercise tests and lung cancer surgical outcome. Chest 2005; 127:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/50\">",
"      Edwards JG, Duthie DJ, Waller DA. Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patients with emphysema. Thorax 2001; 56:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/51\">",
"      DeRose JJ Jr, Argenziano M, El-Amir N, et al. Lung reduction operation and resection of pulmonary nodules in patients with severe emphysema. Ann Thorac Surg 1998; 65:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/52\">",
"      Brenner M, Yusen R, McKenna R Jr, et al. Lung volume reduction surgery for emphysema. Chest 1996; 110:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/53\">",
"      McKenna RJ Jr, Fischel RJ, Brenner M, Gelb AF. Combined operations for lung volume reduction surgery and lung cancer. Chest 1996; 110:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15400/abstract/54\">",
"      DeMeester SR, Patterson GA, Sundaresan RS, Cooper JD. Lobectomy combined with volume reduction for patients with lung cancer and advanced emphysema. J Thorac Cardiovasc Surg 1998; 115:681.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6973 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15400=[""].join("\n");
var outline_f15_2_15400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spirometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diffusing capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Current guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREDICTED POSTOPERATIVE PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Current guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEASUREMENT OF GAS EXCHANGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arterial PO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arterial PCO2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXERCISE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stair climbing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Integrated cardiopulmonary exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Current guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CONCOMITANT VOLUME REDUCTION SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6973|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/8/5249\" title=\"algorithm 1\">",
"      Algorithm for preop eval",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15401="Preeclampsia light micrograph";
var content_f15_2_15401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preeclampsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in preeclampsia showing glomerular endotheliosis. The primary changes are swelling of damaged endothelial cells, leading to partial closure of many of the capillary lumens (large arrows). Mitosis within an endothelial cell (small arrow) is a sign of cellular repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15401=[""].join("\n");
var outline_f15_2_15401=null;
var title_f15_2_15402="Liver transplantation for chronic hepatitis B virus infection";
var content_f15_2_15402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver transplantation for chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15402/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15402/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/2/15402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/2/15402/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/2/15402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in treatment of chronic hepatitis B virus (HBV) infection, liver transplantation remains the only hope for many patients with end-stage liver disease due to HBV. In a study of the natural history of HBV-related cirrhosis in the pre-nucleos(t)ide analogue era, the five-year survival was 71 percent for the entire group of patients, but only 14 percent for those with decompensated disease (",
"    <a class=\"graphic graphic_figure graphicRef57621 \" href=\"UTD.htm?31/3/31805\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial results with liver transplantation for chronic hepatitis B in the 1980s were disappointing, with graft reinfection rates approaching 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In many patients, reinfection was associated with severe and rapidly progressive liver disease, resulting in two-year graft and patient survival of 50 percent compared to 80 percent in those transplanted for other types of chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/5\">",
"     5",
"    </a>",
"    ]. With these poor results and limited supply of donor organs, many centers and third party payers abandoned liver transplantation for patients with chronic hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the late 1980s, the introduction of effective measures to prevent and treat reinfection using strategies involving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) and subsequently nucleos(t)ide analogues have significantly improved the outcome of liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The overall survival of patients transplanted for HBV-related cirrhosis now exceeds 85 percent at one year and 75 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/7,10-13\">",
"     7,10-13",
"    </a>",
"    ]. Furthermore, rates of transplantation for HBV-related end-stage liver disease have dropped substantially, with a 47 percent decrease in liver transplantation waiting list registrations between 1999 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HBV REINFECTION AFTER LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high rate of HBV reinfection after liver transplantation is probably due to enhanced virus replication resulting from immunosuppression and direct stimulatory effects of steroid therapy on the glucocorticoid-responsive enhancer region of the HBV genome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Extra-hepatic reservoirs of HBV, such as peripheral blood mononuclear cells, spleen, and other organs, may also contribute to graft reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors for reinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HBV-related cirrhosis who are eligible for transplantation can be conceptually divided into those with high versus low risk of reinfection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk patients include patients with cirrhosis who are HBeAg positive or HBeAg negative but with high serum HBV DNA levels, and patients with antiviral drug-resistance prior to transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/17-19\">",
"       17-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low-risk patients include patients with fulminant HBV, coinfection with HDV, and cirrhotic patients who are HBeAg negative with low serum HBV DNA levels [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cutoff for high versus low HBV DNA levels in the transplant setting has not been determined. One study of 177 patients reported that HBV recurrence occurred in 50, 7.5, and 0 percent of patients whose serum HBV DNA at the time of transplant were higher than 100,000, 200-100,000, and less than 200",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/19\">",
"     19",
"    </a>",
"    ]. The authors concluded that serum HBV DNA higher than 5 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at the time of transplant was associated with significantly higher risk of HBV recurrence.",
"   </p>",
"   <p>",
"    It should be emphasized that this study included patients transplanted between 1990 and 2002 when HBIG monotherapy and subsequently combination of HBIG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    were the only prophylactic therapies available, and HBV recurrence rate in the high risk group was 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/19\">",
"     19",
"    </a>",
"    ]. With the approval of new antiviral therapies and a goal to reduce HBV recurrence to near zero, a lower HBV DNA cutoff such as 100 or 1000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    may be more appropriate for risk stratification and antiviral therapy should be considered in all patients with detectable serum HBV DNA prior to transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     De novo HBV infection/reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a hepatitis B surface antigen (HBsAg) negative recipient acquiring HBV infection following liver transplantation from a hepatitis B core antibody (anti-HBc) positive donor is generally low, but rates as high as 80 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of acquiring HBV infection may be higher from donors who are HBsAg negative but anti-HBc positive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. One of the largest studies to address this issue found that hepatitis B (HBsAg positive hepatitis) developed in 18 of 23 (78 percent) recipients of liver transplants from anti-HBc positive donors, compared to only 3 of 651 (0.5 percent) recipients of livers from anti-HBc negative donors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/24\">",
"     24",
"    </a>",
"    ]. The HBV infection was mild in most cases; 50 percent of patients had normal serum aminotransferases, while 85 percent had no or only mild inflammatory activity on liver biopsy one year after transplantation. Nevertheless, liver transplantation from an anti-HBc positive donor was associated with a decreased four-year survival.",
"   </p>",
"   <p>",
"    Eliminating livers from anti-HBc antibody positive individuals could result in a significant reduction in the potential donor pool, particularly in countries where HBV infection is endemic. Optimal strategies to prevent de novo infection in this setting have not been established. Reserving livers that are anti-HBc positive for recipients with chronic hepatitis B is one potential approach, since such patients will be receiving hepatitis B antiviral prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Recipients who have hepatitis B surface antibody (anti-HBs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-HBc at the time of transplantation are also less likely to develop de-novo infection after receiving a graft from an anti-HBc positive donor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/20,22-24,26-31\">",
"     20,22-24,26-31",
"    </a>",
"    ]. The lowest risk of de novo infection is in recipients who are anti-HBs and anti-HBc positive. Intermediate risk is seen in recipients who are anti-HBs positive and anti-HBc negative (mean 21 percent) or are anti-HBs negative and anti-HBc positive (mean 12 percent). The highest risk is seen in patients who are both anti-HBs and anti-HBc negative (mean 76 percent).",
"   </p>",
"   <p>",
"    Various prophylactic regimens have been reported to prevent de novo HBV infection when livers from HBsAg negative, anti-HBc positive donors are transplanted into HBsAg negative recipients. Many were based upon regimens that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/32\">",
"     32",
"    </a>",
"    ]. However, most studies involved small numbers of patients with short duration of follow-up. In a systematic review looking at patients who received livers from donors who were HBsAg negative and anti-HBc positive, the rate of de novo HBV infection in 110 patients given lamivudine prophylaxis was 3.6 percent after a mean follow-up of 25 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which are associated with lower rates of drug resistance, may be more appropriate as life-long treatment will be required but experience with these drugs is still accumulating [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBIG prophylaxis has been studied for recipients who are HBsAg negative. One study included 56 HBsAg negative patients who received livers from HBsAg negative, anti-HBc positive donors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/35\">",
"     35",
"    </a>",
"    ]. HBV infection occurred in 8 of 45 (18 percent) recipients who received prophylaxis compared with 7 of 11 (64 percent) recipients who did not. The rate of infection was highest among HBV-seronegative patients who did not receive prophylaxis (five of five patients) and was intermediate among HBV-immune recipients (two of six patients; 33 percent). HBV- seronegative patients who received prophylaxis also had an intermediate rate of infection (6 of 19; 32 percent). Recipients who were HBV-immune and received prophylaxis had low rates of infection (2 of 26; 8 percent).These data confirm a high rate of transmission of HBV infection from liver grafts of HBsAg negative anti-HBc positive donors. The low efficacy of HBIG in preventing HBV transmission is not surprising because HBIG is not effective in inhibiting HBV replication in the liver.",
"   </p>",
"   <p>",
"    HBIG prophylaxis has also been combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    with improved results compared with HBIG monotherapy. A systematic review examined patients who received livers from donors who were HBsAg negative and anti-HBc positive. The rate of de novo HBV infection in the 73 patients who received HBIG and lamivudine prophylaxis was 2.7 percent after a mean follow-up of 31 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the de novo infection rate for combination therapy with HBIG and lamivudine was similar to that seen for lamivudine monotherapy (3.6 percent), suggesting that the addition of HBIG to the regimen does not provide any added benefit.",
"   </p>",
"   <p>",
"    De novo HBV infection has also been reported after liver transplantation from donors who are serologically negative for HBV markers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/20,36,37\">",
"     20,36,37",
"    </a>",
"    ]. These donors are thought to have occult HBV infection because of the presence of HBV DNA in their sera or liver tissue. Although the risk of reactivation appears to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/37\">",
"     37",
"    </a>",
"    ], routine HBV vaccination prior to liver transplantation may prevent this problem and should be recommended to all liver transplant candidates. Unfortunately, the success of hepatitis B vaccination in this group of older individuals with poor immune response secondary to cirrhosis has been disappointing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactivation of HBV replication has also been reported in recipients who are HBsAg negative, anti-HBc positive pretransplant, and received liver grafts from donors who are HBsAg and anti-HBc negative. In one study of 22 patients, HBV DNA was detected in the liver in five (23 percent) HBsAg-negative, anti-HBc positive patients pretransplant, and in two of these five patients post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/38\">",
"     38",
"    </a>",
"    ]. However, none of the patients became HBsAg positive or developed clinical hepatitis post-transplant. There is no evidence that prophylactic antiviral therapy is necessary in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis and clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV reinfection has traditionally been diagnosed by the reappearance of HBsAg in the serum. Most reinfected patients are also hepatitis B e antigen (HBeAg) positive and have high levels of circulating HBV DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/39\">",
"     39",
"    </a>",
"    ]. Immunohistochemical staining of liver biopsies for HBsAg and hepatitis B core antigen (HBcAg) usually shows intense staining.",
"   </p>",
"   <p>",
"    More recent studies using polymerase chain reaction (PCR) assays have demonstrated that HBV DNA can be detected in serum prior to the reappearance of HBsAg or elevation of aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/40\">",
"     40",
"    </a>",
"    ]. These findings suggest the need to re-examine the definition of HBV reinfection and the criteria for initiating rescue therapy.",
"   </p>",
"   <p>",
"    Reinfection is almost always accompanied by recurrent liver disease which is often severe and rapidly progressive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. If untreated, cirrhosis occurs within one to two years of reinfection.",
"   </p>",
"   <p>",
"    An unusual form of liver disease with severe cholestasis and rapidly progressive liver failure (",
"    <a class=\"graphic graphic_picture graphicRef80015 \" href=\"UTD.htm?29/49/30486\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/39,41,42\">",
"     39,41,42",
"    </a>",
"    ], termed fibrosing cholestatic hepatitis, characterized by prominent cholestasis and extensive fibrosis, was observed in the 1990s. Liver injury in this condition is believed to be a result of direct cytopathic effects of HBV since liver biopsies usually show very high levels of both HBsAg and HBcAg expression. This condition is rarely seen now as a result of early diagnosis of HBV reinfection and availability of effective antiviral therapies.",
"   </p>",
"   <p>",
"    Some patients have detectable levels of HBV DNA in liver or peripheral blood mononuclear cells when tested by sensitive polymerase chain reaction (PCR) assays but remain HBsAg negative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Most of these patients do not have clinical or histologic evidence of recurrent hepatitis B. Whether these patients will eventually develop overt reinfection and recurrent liver disease remains to be determined. These observations underscore the importance of continuous prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION OF HBV REINFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of HBV reinfection includes use of antiviral therapy pre-transplant and continuation of antiviral therapy with or without HBIG post-transplant. This strategy has led to a reduction in HBV reinfection rate to less than 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal goal of antiviral therapy in patients awaiting liver transplantation is to reverse cirrhosis complications and the need for liver transplant. However, liver failure may continue to progress since clinical improvement takes three to six months and HCC can still develop in patients who have clinical improvement. In patients who present late, the goal is to achieve viral suppression, thereby stabilizing liver disease, allowing the patient to receive a liver transplant, and (in those who proceed to transplant) decreasing the risk of HBV reinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice and timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy should be started as soon as possible in patients with HBV-related decompensated cirrhosis and detectable serum HBV DNA, regardless of HBV DNA and alanine aminotransferase levels. Although most studies used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , the high rate of drug resistance and the need for life-long treatment make this a suboptimal therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is attractive as a first-line antiviral agent in nucleoside na&iuml;ve transplant patients because it is more potent, has a low rate of drug resistance, and is not associated with nephrotoxicity (",
"    <a class=\"graphic graphic_figure graphicRef83184 \" href=\"UTD.htm?42/32/43520\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .) Lactic acidosis in patients with severe liver dysfunction had been reported in case series, but the incidence is unclear, and in some cases other factors such as sepsis may be contributory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. One series compared six patients with decompensated cirrhosis receiving entecavir with six patients with non-HBV related decompensated cirrhosis who were not receiving entecavir. Among the patients receiving entecavir, lactic acidosis was seen in one patient who was suffering from septic shock. No lactic acidosis was seen among the patients not receiving entecavir. Lactic acidosis may be a class effect of nucleos(t)ide analogues.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    has been compared with other agents in studies of patients with decompensated cirrhosis who have not yet undergone liver transplantation. In a trial with 191 patients with chronic HBV and decompensated cirrhosis, patients were assigned to treatment with entecavir or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/51\">",
"     51",
"    </a>",
"    ]. Entecavir was superior to adefovir with regard to viral suppression to less than 300",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 60 int.",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    at weeks 24 and 48 (49 versus 16 percent and 57 versus 20 percent, respectively). An improvement in the Child-Pugh score of two or more was seen in 35 percent of patients receiving entecavir and 27 percent of patients receiving adefovir. The mean decreases in MELD score from baseline were 2.6 and 1.7, respectively. The rate of serious adverse events was consistent with advanced liver disease and was similar between those treated with entecavir and adefovir (69 versus 66 percent). There was no significant difference between those treated with entecavir and adefovir with regard to HCC development (12 versus 20 percent) or mortality (23 versus 33 percent). Seven percent of patients treated with entecavir discontinued the medication due to an adverse event, compared with six percent of those treated with adefovir.",
"   </p>",
"   <p>",
"    Another trial assigned 112 patients with HBV and decompensated cirrhosis to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    and found results with entecavir to be similar to those with the other treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/52\">",
"     52",
"    </a>",
"    ]. Viral suppression to less than 400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 80 int.",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    at 48 weeks was seen in 73, 71, and 88 percent of patients, respectively, a decrease in Child-Pugh score of at least two was seen in 42, 26, and 48 percent, respectively, and all groups had a median decrease from the baseline MELD score of 2. Treatment was discontinued due to a treatment-related adverse event in 9, 7, and 4 percent of patients, respectively, with a mortality rate at the end of the 48-week study of 9, 4, and 4 percent, respectively.",
"   </p>",
"   <p>",
"    Many experts have recommended de novo combination therapy but data in support of this approach are not available and it is unclear if combination therapy is superior to monotherapy with drugs that have a high genetic barrier to resistance such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . In a report of a study comparing entecavir monotherapy with entecavir plus tenofovir combination therapy in 379 nucleos(t)ide-na&iuml;ve patients with compensated liver disease, there was no advantage of de novo combination therapy over monotherapy with regard to viral suppression, except in patients who were HBeAg-positive and had very high HBV DNA levels (&gt;10",
"    <sup>",
"     8",
"    </sup>",
"    int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    is associated with a lower rate of drug resistance than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    but nephrotoxicity has been observed in up to 20 percent of pre- and post-liver transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. While many factors such as hepatorenal syndrome and concomitant nephrotoxic medications may contribute to impaired renal function, adefovir is not an ideal first-line antiviral in transplant patients because of its weak antiviral activity and a high rate of primary nonresponse, which is likely to be higher in patients who require dose reductions due to renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    in countries in which it is approved for hepatitis B. The advantage of tenofovir over adefovir is the increased potency resulting in a lower rate of primary non-response, and to date there have been no confirmed cases of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no published data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    in this setting, but given the high rate of drug resistance, it is not an ideal treatment, and we do not use it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon should not be used in decompensated cirrhosis due to frequent and serious side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close monitoring of serum HBV DNA levels is critical to assess response and to detect virologic breakthrough so rescue therapy can be initiated promptly. Virologic breakthrough secondary to drug resistance can be associated with hepatitis flares, worsening liver failure and death, and HBV reinfection post-transplant. Patients who are deemed not to require antiviral therapy at presentation should also be monitored as HBV DNA levels may become higher during follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prophylactic therapies post-transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy should be initiated in the rare patient who is not on treatment at the time of transplant, and continued indefinitely in all patients post-transplant.",
"   </p>",
"   <p>",
"    With the availability of multiple nucleos(t)ides, the role of HBIG is evolving. Many transplant centers still administer HBIG during the early post-transplant period, but the dose and duration of HBIG varies markedly across transplant centers. At our center, HBIG dose regimen is tailored according to the predicted risk of reinfection. High-risk patients receive IV HBIG during the first year, and then HBIG is stopped. Low-risk patients, those with undetectable HBV DNA at transplant in the absence of antiviral therapy or while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (drugs associated with very low risk of resistance), do not receive HBIG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/40,60,61\">",
"     40,60,61",
"    </a>",
"    ]. Other centers have evaluated the replacement of HBIG using HBV vaccines or combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    has been used as monotherapy post-transplant (",
"    <a class=\"graphic graphic_figure graphicRef83184 \" href=\"UTD.htm?42/32/43520\">",
"     figure 2",
"    </a>",
"    ). In a study of 80 patients who all received entecavir monotherapy as prophylaxis, 21 patients (26 percent) had complete viral suppression at the time of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/48\">",
"     48",
"    </a>",
"    ]. After a median follow-up of 26 months post-transplant, 18 patients (23 percent) were HBsAg positive, but 17 of those patients had undetectable HBV DNA. These data indicate that a nucleos(t)ide analogue alone without HBIG might suffice in preventing recurrent hepatitis B, but longer followup is needed to confirm these results. In addition, close monitoring, including possibly liver biopsies, may be needed to confirm that those who remain HBsAg positive do not have evidence of liver damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hepatitis B immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBIG immunoprophylaxis is based upon the rationale that administered anti-HBs will bind to and neutralize circulating virions, thereby preventing graft infection. Anti-HBs also undergoes endocytosis by hepatocytes, interacting with HBsAg within the cells, and decreasing HBsAg secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/63\">",
"     63",
"    </a>",
"    ]. Several studies demonstrated a reduction in reinfection and improved patient and graft survival with strategies involving prophylaxis with HBIG (",
"    <a class=\"graphic graphic_figure graphicRef54193 \" href=\"UTD.htm?12/27/12735\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/9,18,64-67\">",
"     9,18,64-67",
"    </a>",
"    ]. As a result, long-term, high-dose HBIG became the standard prophylaxis for HBV reinfection in most transplant centers in the 1990s, prior to the availability of effective antiviral therapy. With the introduction of effective antiviral therapy, HBIG can often be discontinued after one year in patients at high risk of reinfection, and may not be necessary in patients who are at low risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Dose regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBIG is a polyclonal preparation of human anti-HBs purified from pooled donor plasma. It is usually given intravenously as a 10,000 int. unit bolus dose during the anhepatic phase followed by daily doses during the first week. Subsequent doses are either given monthly or in accordance with anti-HBs titers. A trough anti-HBs titer of at least 100 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    is thought to be protective. However, some studies have suggested that the rate of reinfection can be reduced further in patients with anti-HBs titers consistently above 500 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/18,44\">",
"     18,44",
"    </a>",
"    ]. We use a fixed dose schedule that routinely results in anti-HBs titers of &gt;500 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    during the first year post-transplant in patients who have high risks for reinfection.",
"   </p>",
"   <p>",
"    Anti-HBs titers vary not only from patient to patient but also within the same patient even when HBIG is administered as fixed doses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/18,44\">",
"     18,44",
"    </a>",
"    ]. Serum HBV DNA level at the time of transplant is an important predictor of the half-life of HBIG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Combined with other antiviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated HBIG combined with other antiviral agents. A meta-analysis of two prospective and four retrospective studies where HBIG alone had been compared with HBIG plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    concluded that combination therapy was associated with a significantly lower rate of HBV-related deaths and all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, a systematic review of 46 studies found that patients treated with a combination of HBIG plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    (with our without lamivudine) had a lower recurrence rate than patients treated with HBIG plus lamivudine (2.0 versus 6.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have evaluated strategies involving low-dose HBIG with nucleos(t)ide analogues to reduce the high costs associated with HBIG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An illustrative study included 147 patients who received low-dose HBIG (400-800 int. unit daily for one week then monthly) intramuscularly plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily) following liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/71\">",
"       71",
"      </a>",
"      ]. Before transplantation, patients with detectable HBV DNA received lamivudine (100 mg PO daily). Patient survival was 92 percent at one year and 88 percent at five years. The actuarial risk of HBV recurrence was only 1 percent at one year and 4 percent at five years. Higher HBV DNA titer at baseline was associated with an increased risk of recurrence. The authors estimated that this strategy cost less than 10 percent of the high-dose HBIG strategy. These encouraging results based on a regimen that used low dose HBIG, particularly during the peri-transplant period, need to be confirmed by other investigators. More than 50 percent of patients in this study had undetectable HBV DNA at the time of transplant, potentially contributing to the favorable results.",
"     </li>",
"     <li>",
"      Another study included 34 adults at least 12 months post-transplant who were receiving HBIG and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      prophylaxis and did not have recurrent HBV in the graft [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/72\">",
"       72",
"      </a>",
"      ]. Patients were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      (10 mg daily) or to continue HBIG. Lamivudine was continued in both groups. One patient in the adefovir group became transiently positive for HBsAg. All other patients had undetectable HBsAg and HBV DNA during a median follow-up of 21 months. One patient in the adefovir group had deterioration of renal function requiring dose adjustment and then cessation of adefovir after 15 months. The authors estimated that the adefovir plus lamivudine group was similarly effective but substantially less costly than the lamivudine plus HBIG approach ($8290 versus $13,718 per treatment year).",
"      <br/>",
"      <br/>",
"      These data confirmed that antiviral therapy alone without HBIG is effective in preventing HBV reinfection in selected patients. However, most patients in the study were at relatively low risk; only 7 of 30 had detectable HBV DNA by PCR assay when they underwent transplantation. Furthermore, HBIG was stopped after the most vulnerable period (the first 12 months). Thus, results cannot be generalized to high risk patients or patients in the first year after transplantation.",
"     </li>",
"     <li>",
"      In a third study with 187 patients, HBV recurrence rates were examined in patients who received various HBIG regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/60\">",
"       60",
"      </a>",
"      ]. HBIG was given to 183 patients (98 percent), and 185 patients (99 percent) received at least one nucleos(t)ide analogue. The most common HBIG regimen was low-dose intramuscular injection (39 percent), followed by high-dose intravenous HBIG (25 percent), low-dose intravenous HBIG (21 percent), and finite duration of HBIG (12 percent; median duration 12 months). Overall, HBV recurrence was seen in 13 patients (7 percent). Factors associated with recurrence included male gender, Caucasian race, presence of HBeAg at listing, and serum HBV DNA level &gt;5 log",
"      <sub>",
"       10",
"      </sub>",
"      at listing or at transplantation. Factors not associated with recurrence included virologic breakthrough prior to transplantation, HBIG regimen used, duration of steroid use, and treatment for rejection. These data indicate that low-dose or limited duration of HBIG is as effective as long-term high-dose IV HBIG in the era of potent nucleos(t)ide analogues and availability of rescue therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current formulations with lower protein concentrations rarely cause immune-mediated reactions and premedication is frequently not necessary.",
"   </p>",
"   <p>",
"    HBIG preparations currently in use in the United States do not contain thimerosal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Cost and supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocols that use high dose IV HBIG as described above are expensive (total charges of $80,000 to $200,000 in the first year, including the costs of IV infusion sets and monitoring). In addition, the supply of HBIG is unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/18\">",
"     18",
"    </a>",
"    ]. To reduce the costs of HBIG therapy, attempts have been made to increase the interval between IV HBIG dosing, substitute maintenance IV HBIG with IM administration of 5 mL (approximately 1000 units) HBIG, or to discontinue HBIG after the most vulnerable period.",
"   </p>",
"   <p>",
"    Novel formulations of HBIG are being tested that appear to have longer lasting levels of circulating antibodies, and thus may require less frequent administration and thereby reduce costs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/73\">",
"     73",
"    </a>",
"    ]. The half-life of one of these preparations (OMRI-Hep-B) was significantly longer than standard therapy (22 versus 13 days) in a study involving 15 patients in which the two preparations were directly compared [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/73\">",
"     73",
"    </a>",
"    ]. Further studies are needed to confirm these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Monoclonal anti-HBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of early studies with monoclonal anti-HBs were unsatisfactory, with a high rate of breakthrough infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Several new formulations of humanized monoclonal anti-HBs are in clinical testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     HBIG-induced escape mutants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reinfection in patients receiving maintenance HBIG immunoprophylaxis may be due to inadequate dosing or to the emergence of mutant virus that can escape neutralization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. Most of the mutations involve substitutions of one or more amino acids in the predominant epitope of HBsAg, the \"a\" determinant. Some of these mutations result in decreased binding to anti-HBs and may therefore escape neutralization by HBIG.",
"   </p>",
"   <p>",
"    In one report, there was a significant correlation between the development of \"a\" determinant mutations and the duration of HBIG therapy; cessation of HBIG resulted in reversion to pretransplantation sequences in most instances [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/78\">",
"     78",
"    </a>",
"    ]. In a second study, variants with amino acid changes at residue 144 or 145 were most common; patients infected with these variants had adverse clinical outcomes compared to those who received high dose long-term HBIG but were not infected with these mutant virus (graft failure in 44 and 23 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/79\">",
"     79",
"    </a>",
"    ]. These findings underscore the need for combination prophylaxis.",
"   </p>",
"   <p>",
"    HBIG escape mutants are rare in patients who receive combination prophylaxis with HBIG and nucleos(t)ides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hepatitis B vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active immunization using standard hepatitis B vaccines has been studied to reduce the need for life-long HBIG prophylaxis. Most studies have focused on low risk patients who are more than one to two years post-transplant. The results of the first study were encouraging, but subsequent studies found that response rates were variable and often poor (8 to 80 percent), and anti-HBs titers achieved in the responders were low despite the use of higher doses and multiple courses of vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. More recent studies using new vaccines and adjuvants have been more encouraging but these data need to be confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antiviral strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBIG immunoprophylaxis alone has been less successful in preventing reinfection in patients with detectable HBV DNA (and particularly those with a viral load greater than 100,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    or HBeAg pretransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/9,19,85\">",
"     9,19,85",
"    </a>",
"    ]. Antiviral therapy with nucleos(t)ide analogues before transplant decreases the risk of reinfection by decreasing the amount of circulating virus at the time of transplant and by prolonging the half-life of HBIG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RECURRENT HBV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment for recurrent hepatitis B depends upon prior prophylactic therapy. When possible, antiviral resistance mutation testing should be performed to guide the selection of nucleos(t)ide analogues.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rare patients who received no prophylaxis or HBIG only can be treated with any of the five approved nucleoside analogues:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . Despite the paucity of data, entecavir may be preferred because of the lower rate of drug resistance and lack of nephrotoxicity.",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      prophylaxis are most likely to have developed resistance to lamivudine and will require treatment with an antiviral agent that is effective against lamivudine resistant HBV, preferably addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      de novo who developed resistance to adefovir require addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      . Entecavir is preferred because of the low risk of drug resistance.",
"     </li>",
"     <li>",
"      Patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      as rescue therapy for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      resistance may respond to lamivudine initially but lamivudine resistance mutations may re-emerge within a few months of reintroduction of lamivudine. These patients should undergo resistance mutation testing to guide the selection of treatment. Most patients will likely require the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience with interferon has been disappointing. No consistent effect on HBV replication or liver disease has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, side effects such as neutropenia are frequent and there are concerns about interferon-induced rejection. Transplant recipients are immunosuppressed and have higher viral loads, factors that probably explain the lack of response to IFNa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is well tolerated and can inhibit HBV replication and improve liver disease in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/40,88-91\">",
"     40,88-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in the nontransplant setting, a problem with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is the development of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. In an open label study, for example, 52 patients with chronic hepatitis B after liver transplantation were treated with lamivudine (100 mg once daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/90\">",
"     90",
"    </a>",
"    ]. After one year of follow-up, 60 percent had undetectable HBV DNA and 31 percent lost HBeAg. However, resistant mutants were detected in 27 percent of patients. In another report, the likelihood of emergence of viral resistance was related to high pretreatment serum HBV DNA titers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of drug-resistant mutants are variable. Nonetheless, it is prudent to add an antiviral agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    that is active against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV to prevent progression of liver disease and graft failure. Tenofovir is preferred to adefovir because of its more potent antiviral activity.",
"   </p>",
"   <p>",
"    Several case reports found that patients with recurrent hepatitis B due to combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and HBIG-resistant mutations run a more severe course. In vitro studies showed that combination of these mutations had enhanced HBV replication in the presence of lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adefovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    dipivoxil is a nucleotide analog of adenosine monophosphate, which can inhibit reverse transcriptase and DNA polymerase activity. In vitro and clinical studies showed that it is effective in decreasing serum HBV DNA levels in patients with chronic hepatitis B, and may be useful for treating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant mutants. Adefovir has not been evaluated as a first line treatment in the transplant setting, but it is effective in suppressing HBV DNA replication and in improving or stabilizing liver disease in patients with recurrent hepatitis B and lamivudine resistance. Adefovir should be added in patients with recurrent hepatitis B due to lamivudine-resistant HBV. Because of its potential for nephrotoxicity, it is not a preferred first-line treatment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    has largely superseded adefovir because it can be administered in higher doses, resulting in greater antiviral activity and decreased risk of resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Entecavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary results of a pilot study showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is also effective in suppressing HBV replication in liver transplant patients who developed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/94\">",
"     94",
"    </a>",
"    ]. However, entecavir-resistant mutations are more likely to be selected in the presence of lamivudine-resistant mutations. Entecavir should not be used in patients with lamivudine-resistant HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .) Because of its potent antiviral effects, low rate of drug resistance, and lack of nephrotoxicity, entecavir is an ideal antiviral agent in nucleoside-na&iuml;ve patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Telbivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    in the transplant setting is lacking. Based on experience in nontransplant patients, telbivudine can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Similar to lamivudine, telbivudine should not be used as monotherapy, and if used it should be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    to minimize the risk of drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in the transplant setting is lacking. Based on experience in nontransplant patients, tenofovir is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . Because of the potential for nephrotoxicity, tenofovir is not an ideal drug in the transplant setting in nucleoside na&iuml;ve patients but tenofovir alone or in combination with a nucleoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , is recommended for patients with lamivudine resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reduction of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    increases serum HBV DNA levels. Several studies have suggested that rapid withdrawal of prednisone may improve the long-term course of patients with recurrent HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. As a result, many centers now withdraw steroid therapy after six months in patients transplanted for hepatitis B. Whether cyclosporine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) immunosuppression is preferable in HBsAg positive transplant recipients remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RETRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience with retransplantation for HBV related graft failure has been poor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/2/15402/abstract/3,9,97\">",
"     3,9,97",
"    </a>",
"    ]. However, with the availability of multiple antiviral agents, the need for retransplantation for recurrent hepatitis B has diminished markedly. Prudent use of antiviral therapy, close monitoring for drug resistance, and addition of salvage therapy should prevent graft failure and the need for retransplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination of hepatitis B immunoglobulin (HBIG) and antiviral therapy has reduced recurrent hepatitis B virus (HBV) to less than 10 percent, with resultant improvement in patient and graft survival. With the availability of new antiviral therapies that have lower rates of drug resistance and are effective against",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (LAM)-resistant HBV, reinfection rate has continued to decrease.",
"     </li>",
"     <li>",
"      Patients with HBV-related cirrhosis who are eligible for transplantation should be started on antiviral therapy with a nucleos(t)ide analogue as soon as possible.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       Entecavir",
"      </a>",
"      is preferred for patients who are nucleoside na&iuml;ve or who had prior treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      , while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      is preferred for patients who had prior treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       Entecavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      should be continued post-transplant. Patients with undetectable HBV DNA at the time of transplant may not require HBIG post-transplant, while a short course of HBIG is warranted in patients with detectable HBV DNA at the time of transplant.",
"     </li>",
"     <li>",
"      The choice of treatment for recurrent hepatitis B following liver transplantation depends upon prior prophylactic therapy and presence of drug-resistant mutants:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that patients who received no prophylaxis or HBIG only be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients who received nucleos(t)ide analogue prophylaxis should be tested for antiviral drug resistance mutation to guide the choice of rescue therapy. In general, combination therapy is recommended, and most patients will need a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/1\">",
"      de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/2\">",
"      O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/3\">",
"      Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/4\">",
"      Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/5\">",
"      Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med 1989; 321:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/6\">",
"      Perrillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N Engl J Med 1993; 329:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/7\">",
"      Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/8\">",
"      Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/9\">",
"      Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/10\">",
"      Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol 2013; 58:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/11\">",
"      Steinm&uuml;ller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org/annual_reports/current/default.htm (Accessed on March 08, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/13\">",
"      Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl 2002; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/14\">",
"      Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/15\">",
"      McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/16\">",
"      Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/17\">",
"      Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology 1990; 12:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/18\">",
"      McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/19\">",
"      Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/20\">",
"      Chazouill&egrave;res O, Mamish D, Kim M, et al. \"Occult\" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/21\">",
"      Douglas DD, Rakela J, Mamish D, et al. Transmission of hepatitis B virus Infection from orthotopic donor livers (abstract). Hepatology 1992; 16:49A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/22\">",
"      Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/23\">",
"      Prieto M, G&oacute;mez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/24\">",
"      Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/25\">",
"      Kim KM, Choi H, Hwang S, et al. Efficacy of combination prophylaxis with short-term HBIG and long-term lamivudine in preventing de novo hepatitis B infection in orthotopic liver transplant recipients HBcAb positive donors (abstract). Hepatology 2000; 32:292A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/26\">",
"      Mu&ntilde;oz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002; 8:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/27\">",
"      Manzarbeitia C, Reich DJ, Ortiz JA, et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002; 8:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/28\">",
"      Douglas DD, Rakela J, Wright TL, et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/29\">",
"      Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/30\">",
"      Donataccio D, Roggen F, De Reyck C, et al. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 2006; 19:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/31\">",
"      Barcena R, Moraleda G, Moreno J, et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006; 12:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/32\">",
"      Yu AS, Vierling JM, Colquhoun SD, et al. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/33\">",
"      Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 2010; 16:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/34\">",
"      Chang MS, Olsen SK, Pichardo EM, et al. Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl 2012; 18:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/35\">",
"      Roche B, Roque-Afonso AM, Sebagh M, et al. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl 2010; 16:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/36\">",
"      Huang EJ, Wright TL, Lake JR, et al. Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation. Hepatology 1996; 23:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/37\">",
"      Ghisetti V, Marzano A, Zamboni F, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004; 10:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/38\">",
"      Abdelmalek MF, Pasha TM, Zein NN, et al. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003; 9:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/39\">",
"      Demetris AJ, Todo S, Van Thiel DH, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol 1990; 137:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/40\">",
"      Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/41\">",
"      Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/42\">",
"      Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/43\">",
"      Naumann LJ, Berg T, Lin S, et al. Residual hepatitis B virus (HBV) DNA in HBsAg negative patients after liver transplantation (OLT) for HBV induced cirrhosis (abstract). J Hepatol 1999; 30(Suppl 1):67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/44\">",
"      Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/45\">",
"      F&eacute;ray C, Zignego AL, Samuel D, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/46\">",
"      Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/47\">",
"      Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/48\">",
"      Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/49\">",
"      Marzano A, Marengo A, Marietti M, Rizzetto M. Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis 2011; 43:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/50\">",
"      Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/51\">",
"      Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/52\">",
"      Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/53\">",
"      Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na&iuml;ve patients with chronic hepatitis B. Gastroenterology 2012; 143:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/54\">",
"      Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/55\">",
"      Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/56\">",
"      Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/57\">",
"      Lavine JE, Lake JR, Ascher NL, et al. Persistent hepatitis B virus following interferon alfa therapy and liver transplantation. Gastroenterology 1991; 100:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/58\">",
"      Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/59\">",
"      Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/60\">",
"      Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/61\">",
"      Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/62\">",
"      Liver Transpl 2013; 19:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/63\">",
"      Schilling R, Ijaz S, Davidoff M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77:8882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/64\">",
"      K&ouml;nig V, Hopf U, Neuhaus P, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/65\">",
"      M&uuml;ller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/66\">",
"      Samuel D, Bismuth A, Serres C, et al. HBV infection after liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 1991; 23:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/67\">",
"      Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/68\">",
"      Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/69\">",
"      Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/70\">",
"      Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/71\">",
"      Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/72\">",
"      Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/73\">",
"      Adler R, Safadi R, Caraco Y, et al. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 1999; 29:1299.",
"     </a>",
"    </li>",
"    <li>",
"     Fung J, Ostberg L, Shapiro R, et al. Human monoclonal antibody against hepatitis B surface antigen in preventing recurrent hepatitis B following liver transplantation. In: Viral Hepatitis and Liver Disease, Hollinger FB, Lemon SM, Margolis HS (Eds), Williams &amp; Wilkins, Baltimore 1991. p.651.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/75\">",
"      McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/76\">",
"      Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/77\">",
"      Hawkins AE, Gilson RJ, Gilbert N, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996; 24:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/78\">",
"      Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/79\">",
"      Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/80\">",
"      Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/81\">",
"      Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/82\">",
"      S&aacute;nchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/83\">",
"      Rosenau J, Hooman N, Hadem J, et al. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/84\">",
"      St&auml;rkel P, Stoffel M, Lerut J, Horsmans Y. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 2005; 11:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/85\">",
"      Muller R, Samuel D, Fassati LR, et al. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. J Hepatol 1994; 21:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/86\">",
"      Dickson RC, Terrault NA, Ishitani M, et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006; 12:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/87\">",
"      Wright HI, Gavaler JS, Van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/88\">",
"      Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/89\">",
"      Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/90\">",
"      Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/91\">",
"      Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/92\">",
"      Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/93\">",
"      Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/94\">",
"      Shakil AO, Angus P, Gerken G, et al. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B (abstract). Hepatology 2001; 34:619A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/95\">",
"      Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology 1991; 13:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/96\">",
"      Gish RG, Keeffe EB, Lim J, et al. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol 1995; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/2/15402/abstract/97\">",
"      Crippin J, Foster B, Carlen S, et al. Retransplantation in hepatitis B--a multicenter experience. Transplantation 1994; 57:823.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4584 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-55CBC6BF0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15402=[""].join("\n");
var outline_f15_2_15402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HBV REINFECTION AFTER LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors for reinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      De novo HBV infection/reactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis and clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION OF HBV REINFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice and timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prophylactic therapies post-transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hepatitis B immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dose regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Combined with other antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cost and supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monoclonal anti-HBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - HBIG-induced escape mutants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hepatitis B vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antiviral strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT OF RECURRENT HBV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adefovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Entecavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Telbivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reduction of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RETRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4584|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/3/31805\" title=\"figure 1\">",
"      Survival with HBV cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/32/43520\" title=\"figure 2\">",
"      Hepatitis B surface antigen seroclearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/27/12735\" title=\"figure 3\">",
"      HBIG post liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4584|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/49/30486\" title=\"picture 1\">",
"      Fibrosing cholestatic hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_2_15403="Material safety data sheet";
var content_f15_2_15403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimal information requirements for the material safety data sheet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Chemical identity as it appears on the label",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manufacturer's name and contact information, preparation date",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hazardous ingredients, permissible exposure limits, threshold level value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical and chemical characteristics of the substance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fire and explosion hazard data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactivity data such as chemical instability, substances the product may react with, hazardous byproducts, hazardous polymerization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Health hazard data such as route of entry, carcinogenicity, signs and symptoms of exposure, emergency and first aid procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precaution for safe handling and use, including steps to be taken if spilled or released, waste disposal method, precaution for handling and storage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Control measures including protection methods and equipment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15403=[""].join("\n");
var outline_f15_2_15403=null;
var title_f15_2_15404="Opioid receptors";
var content_f15_2_15404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opioid effects by receptor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Traditional*",
"      </td>",
"      <td class=\"subtitle1\">",
"       IUPHAR*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical Effects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       &micro;1",
"      </td>",
"      <td rowspan=\"5\">",
"       MOP",
"      </td>",
"      <td>",
"       Supraspinal analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peripheral analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sedation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Euphoria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prolactin release",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       &micro;2",
"      </td>",
"      <td rowspan=\"7\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Spinal analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physical dependence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastrointestinal dysmotility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pruritus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bradycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Growth hormone release",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       &kappa;1",
"      </td>",
"      <td rowspan=\"3\">",
"       KOP",
"      </td>",
"      <td>",
"       Spinal analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Miosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diuresis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       &kappa;2",
"      </td>",
"      <td rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Psychotomimesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dysphoria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &kappa;3",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Supraspinal analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       &delta;&nbsp;",
"      </td>",
"      <td rowspan=\"2\">",
"       DOP",
"      </td>",
"      <td>",
"       Spinal and supraspinal analgesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Modulations of &micro;-receptor function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Nociceptin/orphanin",
"      </td>",
"      <td rowspan=\"2\">",
"       NOP",
"      </td>",
"      <td>",
"       Anxiolysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Analgesia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * International Union of Pharmacology Committee on Receptor Nomenclature has recommended new naming schema to replace traditional Greek nomenclature.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15404=[""].join("\n");
var outline_f15_2_15404=null;
var title_f15_2_15405="Religious position medical therapy";
var content_f15_2_15405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Jehovah's witness religious position on medical therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unacceptable treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transfusion of allogeneic whole blood, red blood cells, white cells, platelets, or plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoperative autologous blood donation (PAD or predeposit)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acceptable treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most surgical and anesthesiological blood conservation measures (eg, hemostatic surgical instruments, controlled hypotension/hypotensive hemostasis, regional anesthesia, minimally invasive surgery, endovascular therapy, intraoperative positioning, maintenance of normothermia, meticulous hemostasis and surgical technique)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most diagnostic and therapeutic procedures (eg, phlebotomy for laboratory testing, angiographic embolization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synthetic oxygen therapeutics (eg, perfluorochemicals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonblood volume expanders (eg, saline, lactated Ringer's, hydroxyethyl starches)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pharmacologic agents that do not contain blood components or fractions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs to enhance hemostasis (eg, tranexamic acid, epsilon-aminocaproic acid, aprotinin, desmopressin, conjugated estrogens)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hematopoietic growth factors and hematinics (eg, albumin-free erythropoietin, iron)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Recombinant products (eg, albumin-free coagulation factors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Topical hemostatic agents (eg, collagen, gelatin-based hemostats, oxidized cellulose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Personal decision (acceptable to some, declined by others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood cell salvage* (intraoperative or postoperative autotransfusion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute normovolemic hemodilution*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraoperative autologous blood component sequestration* (including intraoperative plateletpheresis, preparation of fibrin gel, platelet gel, platelet-rich plasma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiopulmonary bypass",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apheresis",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemodialysis",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma-derived fractions (eg, immune globulins, vaccines, antivenins, albumin, cryoprecipitate",
"        <sup>",
"         &Delta;",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemostatic products containing blood fractions (eg, recombinant factor VIIa",
"        <sup>",
"         &loz;",
"        </sup>",
"        , coagulation factor concentrates, prothrombin complex concentrate, fibrin glue/sealant, hemostatic bandages containing plasma fractions, thrombin sealants)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Products containing plasma-derived blood fractions such as human serum albumin (eg, some formulations of erythropoietin, streptokinase, G-CSF, vaccines, recombinant clotting factors, nuclear imaging products)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen therapeutics and other products containing a blood cell-derived fraction, whether from a human or animal source (eg, conjugated hemoglobin solutions, iron supplements, hematin, interferon alfa-N3 (leukocyte derived))",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural blood patch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood cell scintigraphy (eg, radionuclide tagging for localization of bleeding)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral blood stem cell transplantation (autologous or allogeneic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transplants (organ, marrow, bone)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients might request that continuity is maintained with their vascular system.",
"     <br>",
"      &bull; Circuits not primed with allogeneic blood.",
"      <br>",
"       &Delta; Cryoprecipitate resuspended in 0.9 percent Sodium Chloride Injection (USP) diluent (ie, vast majority of cryoprecipitate preparations).",
"       <br>",
"        &loz; Recombinant activated Factor VII currently contains trace amounts of murine and bovine IgG from the manufacturing process.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfusion Med Rev 2004; 18:105. Copyright &copy;2004 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15405=[""].join("\n");
var outline_f15_2_15405=null;
var title_f15_2_15406="Meibomian gland dysfunction 3";
var content_f15_2_15406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meibomian gland dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plugging of the Meibomian gland orifices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Foulks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15406=[""].join("\n");
var outline_f15_2_15406=null;
var title_f15_2_15407="Balloon dilation";
var content_f15_2_15407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexible bronchoscopic balloon dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Balloon dilation of a circumferential mainstem stenosis that developed after lung transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Armin Ernst, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_2_15407=[""].join("\n");
var outline_f15_2_15407=null;
